var title_f10_19_10544="Single fiber and concentric needle electrodes";
var content_f10_19_10544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single fiber and concentric needle electrodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Single fiber electrode, recording area 25 &micro;m in diameter.",
"    <br>",
"     (B) Concentric needle electrode, recording area 580 x 150 &micro;m.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Based on information from: St&aring;lberg E, Trontelj JV. Single fibre electromyography, The Mirvelle Press, Woking, Surrey 1979.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10544=[""].join("\n");
var outline_f10_19_10544=null;
var title_f10_19_10545="Macroglossia in a patient with Beckwith-Wiedemann syndrome";
var content_f10_19_10545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Macroglossia in a patient with Beckwith-Wiedemann syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10545=[""].join("\n");
var outline_f10_19_10545=null;
var title_f10_19_10546="Patient information: Esophageal stricture (The Basics)";
var content_f10_19_10546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17228\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"         Upper digestive tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"          Upper endoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/30/38373\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/0/21506\">",
"         Patient information: Upper endoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Esophageal stricture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/esophageal-stricture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27271331\">",
"      <span class=\"h1\">",
"       What is esophageal stricture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An esophageal stricture is a narrowing of the esophagus, the tube that connects the mouth to the stomach (",
"      <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"       figure 1",
"      </a>",
"      ). People can get an esophageal stricture if they have had a disorder called &ldquo;gastroesophageal reflux disease&rdquo; (also called GERD) for a long time. In people with GERD, acid from the stomach backs up into the esophagus. Over time, the acid can scar the esophagus and make it more narrow.",
"     </p>",
"     <p>",
"      Other causes of esophageal stricture include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Previous surgery on the esophagus",
"       </li>",
"       <li>",
"        Radiation therapy",
"       </li>",
"       <li>",
"        Swallowing a substance that harms the esophagus, such as household cleaners, lye, or disc-shaped batteries",
"       </li>",
"       <li>",
"        Treatment for esophageal varices (enlarged veins in the esophagus)",
"       </li>",
"       <li>",
"        Cancer",
"       </li>",
"       <li>",
"        An allergic condition called &ldquo;eosinophilic esophagitis&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27271346\">",
"      <span class=\"h1\">",
"       What are the symptoms of esophageal stricture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is having trouble swallowing (called &ldquo;dysphagia&rdquo;). You might also feel like your food or pills are getting stuck in your throat. At first, you might have trouble swallowing only when you eat solid foods. But as the condition gets worse, you can have trouble swallowing liquids.",
"     </p>",
"     <p>",
"      If you have acid reflux, you might also have symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A burning feeling in the chest, known as heartburn",
"       </li>",
"       <li>",
"        Burning in the throat or an acid taste in the throat",
"       </li>",
"       <li>",
"        Stomach or chest pain",
"       </li>",
"       <li>",
"        A raspy voice or a sore throat",
"       </li>",
"       <li>",
"        A cough for no reason",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27271361\">",
"      <span class=\"h1\">",
"       Is there a test for esophageal stricture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have an esophageal stricture, he or she will probably order 1 or both of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"         Barium",
"        </a>",
"        swallow &ndash; For this test you eat a special meal that shows up on X-ray. Then you have X-rays taken to see if the barium gets stuck or slowed down on the way down your esophagus.",
"       </li>",
"       <li>",
"        Endoscopy &ndash; For this test, a doctor puts a thin tube down your throat and into your stomach. The tube (called an &ldquo;endoscope&rdquo;) has a light and a tiny camera on the end. It allows the doctor or nurse to see inside your esophagus (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"UTD.htm?36/39/37490\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27271376\">",
"      <span class=\"h1\">",
"       How is esophageal stricture treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment for esophageal stricture is a procedure to widen the esophagus called &ldquo;esophageal dilation.&rdquo; This is usually done during an endoscopy.",
"     </p>",
"     <p>",
"      If you are having esophageal dilatation, you will get medicines to help you relax. Then the doctor can do the dilatation in 1 of 2 ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Using solid flexible tubes &ndash; For this procedure, the doctor puts a series of solid flexible tubes down your throat. He or she starts with a very narrow size and then inserts wider and wider ones until the esophagus is stretched open.",
"       </li>",
"       <li>",
"        Using a balloon &ndash; For this procedure, the doctor puts a tube with balloon on it through the endoscope into your esophagus. The balloon is then inflated to stretch the narrow part of the esophagus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After having esophageal dilation, most people also need to start taking a medicine called a &ldquo;proton pump inhibitor&rdquo; (also called a PPI). PPIs stop the stomach from making acid and can help the esophagus heal and keep the stricture from coming back.",
"     </p>",
"     <p>",
"      If you still have problems with esophageal strictures after repeat dilations, there are other treatment options your doctor might suggest.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27271391\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       Patient information: Upper endoscopy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/19/10546?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17228 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-3C9D172F08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10546=[""].join("\n");
var outline_f10_19_10546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27271331\">",
"      What is esophageal stricture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27271346\">",
"      What are the symptoms of esophageal stricture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27271361\">",
"      Is there a test for esophageal stricture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27271376\">",
"      How is esophageal stricture treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27271391\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17228\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"      Upper digestive tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"       Upper endoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_19_10547="H pylori in gastric pits";
var content_f10_19_10547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Helicobacter pylori in gastric pits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dieterle's silver strain (x200).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10547=[""].join("\n");
var outline_f10_19_10547=null;
var title_f10_19_10548="Iodine: Drug information";
var content_f10_19_10548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iodine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/55/19315?source=see_link\">",
"    see \"Iodine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iodex&reg; [OTC];",
"     </li>",
"     <li>",
"      Iodoflex&trade; [OTC];",
"     </li>",
"     <li>",
"      Iodosorb&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiseptic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cleaning wet ulcers and wounds",
"     </b>",
"     (Iodosorb&reg;, Iodoflex&trade;): Apply to clean wound; maximum:  50 g/application and 150 g/week. Change dressing ~3 times/week; reduce applications as exudate decreases. Do not use for &gt;3 months; discontinue when wound is free of exudate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Antiseptic for minor cuts, scrapes, burns",
"     </b>",
"     : Apply small amount to affected area 1-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      RDA:",
"     </b>",
"     Oral: 150 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pregnancy: 220 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Breast-feeding: 290 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2521617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/55/19315?source=see_link\">",
"      see \"Iodine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      RDA:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1-8 years: 90 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     9-13 years: 120 mcg/day",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     &ge;14 years: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F183686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dressing, topical [gel pad]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodoflex&trade;: 0.9% (3s, 5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodosorb&reg;: 0.9% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodex&reg;: 4.7% (30 g, 720 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, topical [mild]: 2% (59 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, topical [strong]: 7% (30 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, swabstick, topical [mild]: 2% (50s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tincture",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2521619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Iodosorb&reg;: Apply",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     \" to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     \" thickness to dry sterile gauze, then place prepared gauze onto clean wound. Change dressing when gel changes color from brown to yellow/gray (~3 times/week). Remove with sterile water, saline, or wound cleanser; gently blot fluid from surface leaving wound slightly moist before reapplying gel.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used topically as an antiseptic in the management of minor, superficial skin wounds and has been used to disinfect the skin preoperatively",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F183695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Iodine may be confused with codeine, Iopidine&reg;, Lodine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reactions reported following topical application: Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: TSH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Eczema, edema, irritation, pain, redness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Reactions reported more likely observed following large doses or chronic iodine intoxication; frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash, angioedema, urticaria, acne",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Metallic taste, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemorrhage (mucosal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Swelling of eyelids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Ioderma, lymph node enlargement",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2521604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodine or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodosorb&reg;, Iodoflex&trade;: Hashimoto thyroiditis, history of Grave&rsquo;s disease, or nontoxic nodular goiter; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2521605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodosorb&reg;: For use as topical application to wet wounds only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not for application to large areas of the body or for use with tight or air-excluding bandages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: When used for self-medication (OTC), do not use on deep wounds, puncture wounds, animal bites, or serious burns without consulting with healthcare provider. Notify healthcare provider if condition does not improve within 7 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2521600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An adequate amount of iodine intake is essential for thyroid function. Iodine crosses the placenta and requirements are increased during pregnancy. Iodine deficiency in pregnancy can lead to neurologic damage in the newborn; an extreme form, cretinism, is characterized by gross mental retardation, short stature, deaf mutism, and spasticity. Large amounts of iodine during pregnancy can cause fetal goiter or hyperthyroidism. Transient hypothyroidism in the newborn has also been reported following topical or vaginal use prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2521602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2521603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iodine is excreted in breast milk and is a source of iodine for the nursing infant. Actual levels are variable, but have been reported as 113-270 mcg/L in American women. Application of topical iodine antiseptic solutions can be absorbed in amounts which may affect levels in breast milk. Exposure to excess iodine may cause thyrotoxicosis. Skin rash in the nursing infant has been reported with maternal intake of potassium iodide.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2521618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some dietary sources of iodine include cow's milk and dairy products, fish, seaweed, eggs, chocolate and iodized salt.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2521621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thyroid function should be monitored in pregnant women, neonates, and young infants if repeat applications over large areas are needed.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kelp (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2521610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iodine is required for thyroid hormone synthesis. Iodine is also known to be a powerful broad spectrum germicidal agent effective against a wide range of bacteria, viruses, fungi, protozoa, and spores. Iodosorb&reg; and Iodoflex&trade; contain iodine in hydrophilic beads of cadexomer which allows a slow release of iodine into the wound and absorption of fluid, bacteria, and other substances from the wound",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2521612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Topical: Amount absorbed systemically depends upon concentration and characteristics of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Primarily trapped by the thyroid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&gt;90%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/19/10548/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorea JG, \"Iodine Nutrition and Breast Feeding,\"",
"      <i>",
"       J Trace Elem Med Biol",
"      </i>",
"      , 2002, 16(4):207-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/19/10548/abstract-text/12530582/pubmed\" id=\"12530582\" target=\"_blank\">",
"        12530582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linder N, Davidovitch N, Reichman B, et al, \"Topical Iodine-Containing Antiseptics and Subclinical Hypothyroidism in Preterm Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1997, 131(3):434-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/19/10548/abstract-text/9329422/pubmed\" id=\"9329422\" target=\"_blank\">",
"        9329422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mestman JH, \"Diagnosis and Management of Maternal and Fetal Thyroid Disorders,\"",
"      <i>",
"       Curr Opin Obstet Gynecol",
"      </i>",
"      , 1999, 11(2):167-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/19/10548/abstract-text/10219918/pubmed\" id=\"10219918\" target=\"_blank\">",
"        10219918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8988 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10548=[""].join("\n");
var outline_f10_19_10548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183691\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183685\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521617\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183686\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183680\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183670\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521619\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183681\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183695\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183689\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521604\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521605\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299526\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221077\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521600\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521602\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521603\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521618\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521621\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038658\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521610\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2521612\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8988|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/55/19315?source=related_link\">",
"      Iodine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_19_10549="Chronic rejection Light I";
var content_f10_19_10549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing chronic renal transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDs9F0/SJ5onisraHyotgYKAVAIwowOnXv/ADq3d2qOCmniOCOJhjcqhW4ycDrj8ufzqTTp1meZZo4Y7iHCsQDjBHXoOenerSxGJYLu93ky5KgqAy/5/KvQbtI+ynO0/wBDElNzFH5FrYm4hkOWiWP5VOcsxz1559R1quFif7LLbxQIUfL4Vdyt6c9B74rZAMcbMdTcz7chXTajdwRjOP8A61Z9qkMigahbYnc+YzIcqzY6nuDzVxZtCatexpW88NreKZLRmJTIw5+ZyRjGBgjrzWVq6eVdNqSPGZJFZFiUsGBHYrjrya2F1eK3HkwxeeqDbu3fKuPfvWLbia3mMt87OsxLuj4G3njawwcfWiCad7f8H/ImlzKXNb8d/wDItT6VbXGk2twwmuWuNvzSRnKjkqWxwMZPPvU0dlcxPNP9pAKMiMFK5OeQD6d+p/ngxxa/ImYUYvxiJVOGB6nk9en8qhuL7VLW6S40uXzZJ9qz7kX5l55IxjPPfAo5am2nzGvau8W15X/4bTQb/wAJKW1KSynWXyh8sryR7NgIGMH6n69+nNaunfZrmwUwXkUkpPyzjByM9Mfp+FRTwQ63LJvC2moHEmWTy0Zj/EoyRn1yOahvNNk0w+ZHCIijA7AT5TL3OB0PTpjpU3T02YSdKSUY+7L+vz/4cbGl0hkewAdw5Ulz8hKnB/rV8XV6oQJbMTn5mRsHGO3/AOui2uTPDFN5bRjcVZZMkN3GG7cfmRUN5YSPFbT6fezSKmFfKruPvx1/D1NVe71M3JN2nYs3rW+9bl1KzgbfMU4LD0I6GmWy26yRsExcbcLOEwy5IJAPYEgZA/8Ar0umwTMkZmdUkPG1furj6gH86nimKXEobypYRlGkxnYehBx0/CpfZENpLlQlxO8awzBEkIc7skKV4I3DOOecHvzWhNp1vqmlo8SeRd+WXGF3LnGPofxrnpb+1sdUDxm4YlghRi5AOcZHHHP/ANety01+MC2W5VZTMpRzGP8AVnA+Ud8detTOMlZxRnVhUVpU0Zuni/0+ZjmMWRACxEYDNnnd1wP8c1YsXjW3naKViN7NFE+Rt/2cn/P0rUuLdJElkglaFm6CUDbkc5H51lXrubR4XjhcyHlmYhVPYgd+QOlNS5wU1V1tqWJMxbNTa2k82JdoKFSQOeDgkH86syXtrehYNShWRZQGUMvBxyPxFYEySQSxRRXBtY5wHYLJlC4P3AG9R6/pWxdxJDHDcfZJ2Tnfhd+0jGDjrzSlFK1yZQjdX+Xc6Ga4ikgjltWIliB/d53bgT9enf2rEksbCzuGu7KIi5mj24GQq92+p6D8KoQ6jLa3YkRN8b/MZ9oG0DOVYdRj/OK6FrO01Sx8y3u5IzOqyKFP3QR1A7de1Zcvs99jn5PYOzej/rUx7hrVb+JhOyXkCs7KUzhSecseOpBHPb24saVNYRi7R4JUto8MLuVCSzdyeMEdPmqG/tYLGOSC9jdI22gyAFhIS3bIySO4p2ozQO0Q06VbeeOVXuMEAbcDPbAJGPTNXZSSReklbXXqaX9qXGmWl/qMVpJPHGjFoVQhpSM4Kdc7uw68ipd+i3twk09vcwux3GMIxycc5C55/r61lz61bXIuoYojLKdsZ85CkUnzdAGBXOPb/wCs/wA+GK2his5I7QSTsI3jRZFyOWAIJx368+1Z8jWr0Zj7P7Wqb7drf10L97ff2tOul6dbItvG26RsAbMMCDt+uD61QttUfSr0vZ3FxeQqSJkfgDgYI/Kqi3U895thkWO4WbPm2p8xGXn/AFhHQnGcc9RU0Oh3bzh7q5uJ1+ZxhgFTvgqOv4irSjFWlsWqcIR5ZWsdJ4l00azpMd1Zj/SAN0Z6EBh8w9zjn6gfWvPLCz8Qec2larYNcxHH8QKjPcHrjOa7mDW/7F0pRPBcyLEBu2AOQBgHgfnirGuahoLtDb6tNFFLcHERYkEEZOc9uh59RUU5yh7trr+tjLD4iphk6bjzR6Pdr0OQ0jwRFolz/a+ozFY7c+ZHBG2eQeNx/p+tX5be5u7W5lb7QjzqXSUDPzDkHHHHGADwadrc9vrOlytaakb6BQoVLaQIRzwSfT3qvd3Vw00kcrFHil2IEcnYq8DqB1AB/HitbznrJ6/kdSqVq7U6jvL8kvL8xmgaFdpphaVrVjGSbZV+XPORuB6En8qk1mP7DBHDZrI0ciI5Zmyu3PJ7HHP8unbajuotMkaO4kRVMaPLzlo5G4OfrxULm+lu/IvWRlCqVnKYXPQj0B71n7STnzPYw9rKU+aWxm7Y2jiWC7WCRxlXUc/Xng9RmpNV0wyWLfbz5yPkXPlMORtGD228gNxjkk85qTV9PgtrOW4knlEgyoPKDOf4QR69/wAql0fVYrGBLW6SSSExg+cg38jjDY46Cm3zLmjqV7SSSqU9Wjk9N0+PTEN9fytbTbRbRF1YxbzkcEHkEbeT06Z9OjheePbLd2rhgrfMjBowEJIfGfvE+vNPivo5TLHAkt/bkmUFsbd2RhckDGMZGap6lp8t9bCPTbvEsTqrGYLujOcjAICn8O+aptyfvf1/Xma1KvtpXqafkv8AL5lltZs7u+NjPfsHj2NKnl+X5Y9/fkfn7VL4rfyb6R5TtXjBPYYrC1Cze/isplexFyzmKaQuV3xkEEZHU8Ad8da7W3tLbW9NSPULdDKn7twrkkYPHPBqHam1L7zOo6dBwqLbZ7f8A5bQ7lbnV0tBllkGXGeCo69PTHH+crBpt4L6+kuhLdyWq/6NDJKSuQdoJGepAzmum0DwtbaNezzxO7hxiMyHcQvU9vXH5Vznie9NlHqctgHM8c2WhY/69T97A64Gc8elPnVSdoeRUa6rVnChs7L8f6RirBcarYarFcQpJdDc0TyrjY3YAexGce1bX9oz22hw3dzkhXECy4AwThSfYcfWr+l2815azPfQOLgohLAlVJHzAAA5wOhz1rUa3guvC7WZNtN+78vEa/Ln2BJ6e9KdRN7dRVMTFySa0v8AnvYydKkSGzgkuLWY3KZkaZBuBZvl4yQSdoHatU2lvf3RvYJN08S7HR1AHUHkevuD29q5d7TVdLtUmmui0UYLywygFT8vqRng/TFPl1uKwtzewXVsEcASK8oO5eRkAZPU45x70ODlrFmcqMpvmpu7fb8iz4ntTFA0UNxHHdTHZEDJyhwenYDuTWQLrxDEBGut6cAnygGX0pEit5JRPeXceSxMfmncSoyeW9uTzWRJNZB2AlkGCeNyCtYU21b9Dtow05Gk7d0MiZbS6kCGeaaVywmC56ZwCewwT1/XFVruW8u4QtrJJA0DfLtHQcnj1HNWb2zhnk1W3mkCbETyXL7NxbB5PPdT25zSk/ZZUaC3uJ4jtwwYvsXHXBHToeTW0Zdlqeh7r13f/ART0/VWvNQVJpxDdlgvnNGSoII45x64rb1aGMoI1Bkmd8FmPA+np061DcBZY5UEMe1ogwkdMgNnmi3xNI80Y8xl4UZ7/T/PWn15loYNJvmWiRDcl7WVbeEfulwS3tnrj9AKqxW0l5ehnLct8gbtVyRGE25n8w8DHv1NWLQQwpNJISzj5OnAz1Huavm5VpuaKXLHzKbWiQy9UMwGF2r9wH096RreM3B2s8bJy8hP3sdvpVkyx2kbS7QWJxyc5zxU9paXFwhlkAWEcKMcMfr3pOVtWJztqypG9/plwHgldY5/mQOnCgD+ufarVvq1vJcbruATypgFkPzc/wCTUk8RmDPeNiJeE6/MfQD/AD0rKV7eG6l8yPykQgsw6se2f5etJJTWq1ElGa1WvkdGt/aRSxG2KPACWkilXafYjFaFl/Zl9O00MLp/exwufUr0/HFc0tsJlUmZAm3liNuB1xjpmmsj29nF9geaPJz5o+8Rn0IOc+lZuknonqYTw8ZfC3c3tX0uSZYzp6p5LOQXL4CHHBIBGckVnulzazq08cwjH3H4K8g5U4/nSpqVzB5wnkbc4Dq2N4wOo/KpH1SQ6cjKsMtqBtkijG1ogep2jgj6UkprTdEJVYK0kmh7XH22O4tXgjKjBR1cF/LPVgAMkj09qzorP7LcHyQ8sJVdqS/K6+/PfjNbNjo9pJbmSxna1uih2ufmDKeeM+4/Ssi80+8iu9OKSF7KNWguHkILkgZGSc/XNKMo3aTsFOcVJqL+8u22pNG32e5LtCW8vdgsQxIxlcdOetSahp6zxQrIIxwAXjP3cdsHt7ZqnbRNf6f9ptLhZoA27eh6YJ9+DS2YjhS4tbl1nQyF3UDHOeCcemBz7U7Wd1uNxV7wevUZLcaf/pDXs0NvLGwjZjKuV4+VvQd8Grd9dta2sl8L0LaJlXWMggg4A6EdM+tUNR0FVla8jlSS1JJe2kyyIuw/c4ODn+tTWN0riCBLJHRiFZBhg+DwcnjIwTjGePaldNXRbjFpSjquvl5alqyXTtYtLu0sbgtczh3WNYtsWDk/KQODg9z19auaWjnR7axlHlXiAJ91tyHGfwIx3NY+qWkNsk02l3YtohCYpYfLMij6Lntjt69K1YJhZ6f5WrbpXdRHBMMRvhV4VmJGe5yTxUPb3dvx/wAjGorxvF3u9uqf5Gfoaanp97PZtfTXbklvs90crJ67WPf2/Cr4jsbuPUxAhSe4K/aY5gTjGAQM9QQKqa3ZfabywNyjrvVjHLyrp6c45zz+nrVvxDYQz6Ylx50sOoWke63uEOVfjoR649attSal1ZEmrqXV9v6/4JmaPrMSi4j/ALJkhPlBxvBwVxgZXseDVWe6t4bSPFy1peTL9onijUlZVjOc45weM++CM1f8mPXtO077Xd/Z7vY+9Q+3fgAMcde/Tiob8PZXSJcPAbWBwVhf5WZQOgxjBHpyOavRyslr/kaRtzX69V6epqaHNpV1qFmdNC25wDLGSwy6gEA9umeCRjHfNdTc6tDbOReWcsUY6vtyOB2IrltH07R5o5ri3tiBcrvfeSXZmPIz0xz0qzc6ne6XoFzEmmOtjDARAzkswwOFYdefXsOtc1SKlLS/zOWrSVWaUbvpq7fjc1tNSI3m+ygh/s2aMzzXRlKtk5IBUg54xySKo6vY2xeG2860uLd8R+VKVZslSQATnHBP50v2O6CwmxgVMx4xNIWZ0G38MHceuDmsu2vdaZowttZ/6POsY3IiiNVJDLnGRkZxj86mMW3eL+8mEG5c0X97/Pf9Cnd61/wjVo+mXelJIjIxU2gOImxgDGBjjaeD1z0rp9EsrS6tLfU7CZA88SSDzkBIbAwT06Dj8KLu8sLvUY8QpLfsixyoJcfu8n5h64JJ7ZB61alsFktftkCSwuVI8uUBiB7qDj8jn1pSnpro3/WwVaqcFpyye76P5EdvbXenTT3N28N3PcSgc8BF77Tj2PHtj3rB8TX0sizxNEIm8xI45HJ2SbyAMHIxjj2Gasa1qAFlEbhj5UcRaR0DBC3AAJGSDk56nv7Ul7YQazBmOVw6W7RviPc+JFxkrj2/MVUbxfPL+v6/UdGKhJTqIy76+sdKSzbe+omWQqqwy+cseF3Eg9NuMHGe/wBauW8kkksl7ZJbIl2q5nwZUBAA4yRjDBxwOmKybbwn9m0eOym1S9Nuj+dd7vlLxqWIwG5UAseemexNXtD0y+s9KngsraaYLKTueU5MoXliDnIJxx6nNW2rN3O2rGgoe5K7vbXRNX89vx/y3YRBNZu4tALiIZ8uYHqpIBwM9xkfhVPxC0rtC0lmBHHF5hnUFgr/AE4PqAfeoNYtfMt7Wa5MkV5GBvWTI+0sAB91W4HXPy5wcitXzXuLKWHymj2L5RaP5mQ8ZAB7Ywc+lQnZqRxJcrU07/p/mVYLkWcULR2cZuJgpldwH25ycfQZ5xSa6t3bvZ3GjQKt5Ijzsikgc4U469d2cYI4P1qK3F7pYdSiyRNIxEtyrFI1zkAYwcnI6ng10Xhq3+3mTUbmWSWSSR0QMNqqgJHy9Mjjr3yaJPl97p+fkRUmqX7x6r8/Izr3WdZ8qO3tntzOAPNZULvHnBBI4Az78ViXEUVzEoubq8ttTdPNNwVP7tVDAO/YKfmr0a5W2to5bgiGH5RulPGcdAT6VwaSwSaekurtdysSyTPCrIgfqcgYBXjHTnPPWlSldaIjDVFNXhG3pu/67F+Q3EqW19YSPNCYxlowOTwc9M4PUfWr1s2zU7K5ljaN54zG0WO4PD47e/1Fc7HqUljoDx2U1zM8B8uO68sRrsL8AZBUhRhaZpep3Eeprf3lw1zDBH5DeYQpjJ6kAAZJwOtN05OL8vvNJUW4tLZXS7vt/TOu8RppzWyNqaqyA5RWxy3bGe+cV5zrMSyeIY7iCWKG23okivHnLAqQcZAJGDyPbj13/tx8VTXMMYkt54AR5LN78HB7kDjj1qq8XmNPa3drLFIMbZWHypkds9cVVKHs9JbmmEToKzeuzXa/kclqmqpD4klt1tMfb1ZYt+Y1kIzjkjhiMDHuPWuktbPw0bWEytpwkKDdumBOcc5JOTWLrOkLrrwaNFvd1ZGScAZBH3sg9QRycdwPSurXwYmBuS5Y9yJFGfwCYFXUny2V7fM7MTKi4QTm4y62/BnDwyPcaxLa3kP7yEpjfJx3KnHY8nPHfvxWjplw88gkjgkgwTGYWbKtjglWxVnxNHahDLvFvcMVXzhC0g255Py8jGevQZ9KytOEmlWMrG4F/bL8sctuh+c57jseeRx0rVSUl5/18jrclVhzJW8tf+GNG8mup7cIkaRRxyYcbs5QDt+PY/rWfp+pfZhPsT55AVVhzkA9cenNbVpa/urkiQBsED5cHGB29awX/wBGvZS8Qzt2JkckdSaunZpxJpqLTiaMEpis/OmKhgDjJ6Dqf8+9NhuPOSCeUPIsgOwKQAgIPzH16Ad+tZdvctqdo6KD5RYx4B6+v+FaUe5hHGsZxyFx/npVuPcpwtuS/ZWvkMbSeVErDLLxjj7orUDbLAO25yMBcjoOwx60hVbXT/KtQTtUlSW79c5NRWt29zK0gAMMedv+0wGM/QdPzrFtv0Rzyblr0QhaaRHZl+cdVPQduPwqRLFQoV1DuMliwAOScmqsd+C8W1RycnHb/PWtCWUNEfNkVkZypZW5weMHuDzQ7p2CTcdNhGj2JtZVLAbSOg//AFVCjRhnkbMfzBWDdAfX9a1ktDJZ71APlrgZOOe2fWoEiSQfMvBXPP8APFQpozjVWpSdJhOmzBi/iHOSfb2qkNNZp2WMmHH8QOOB/ie2a1g8yrLBEHjAAAkHynHrViwe2uolEty3ynnI4P4VXO4rQr20oq6M/T9Xl0lIIWHnclt4O5u/Ix+P5VvR3VpqMQmYxJIzbdwGVc8jGPXg8e1Zk0KOoRIESPbxtYgn9aorZz28iukkmNwPzqGBOcnII+lRKMZarRmcqcKnvLSRdvTBazS+VJ5K4Cq0ZLqDnBGzt1z7Y5rCtrN9oklaOR0OxJY+su4ZDZ/hJ4ODx71tz/Z5inlpM08QcopbaRu67c/U889xTtQtoQxup3CRpGY1hJOGBwd2BwX7e9OMnFWFCpyaCJebLPZc+U7TEROm7IHcbsDriud1PUbfS/FNn9lEltaSLsaFwwV/lbAVSQFJOMH/AGs8d5Luzu4DZSxApZxBBKkZHCAjBO7G44Hp3/NbnRUv4YrhmjBVDEsM3zc542k44IHGRkj8aOWPVnXSVOm+aT0d1/SI9PmmW5t2ub3S4XQmCW2W6QEgrkY525zg8nP9dK31aO5iWaN7mVGZGMDKDjPIcBux4/OqepeF9PudCWyu0kt7pBIyrEmULY+UnBxuA4GMZ+XPAqPw74Pk0YzX/wDaUc1riR3ijDBgQpAG04LZP6A465E8y3l+RVR4acXJys+ito/TffobetalqMqwOIobi0jdWKyxqXIOQ2z0OP51o2CKLNJUSJVA+UvNkjLYA7HONvPvXN6bqVzc3MKy27PFJtQ4bc4JGScAAYB49avXsV2k1vPYb5XQCZCVPlujcdcYzjPBqpU7WjsccqaSUFZG1asl5q9kGSAvbKw3+YQyBgeCoOCDxz2x3pl7pVzJYZ1Oe3u7Y480MhkUjjfgAZyMZH5U0hysV1a2UMctxl3lX922/OMNxx35z1qy2p3aOYLgSQyPHkovOfXB6Z9x7Vjrf3TmfNdOH9d7dhlro8GlT2sVq9rIseElO/a2CM42c+ucZ6UC50pGvE1sQvcyMu9hGXQddnByARnr71qL9l1REgvS8Vwhz8xGW9CeAM1ntps8F1PJCk89vHh9p53kdhk+3oBzS5ub43r/AF1MlLmbVRtP+upc1uC4NxaXSXepizVRlLbDeaSCAGULkZyOen06jnxdx2Frc2t6H+0bvOaYxkhC/LhmwACCTyOOhrZsNbaGzLeRIhmfiJlJKE/y/l1rn7y5juYLiL+y4vMUMAZYyQVO5jsIbAJJznI64ohCS0a0Rth4te5NaLtYhYm1kvLSzTFyNolc/fYt90kgg8Yxk4NIuralBKtk005lwGkZRjyl6ZBPXke9RX2mrc+E9/8AbEkkjzLJ+9C4ZjtBTIB4AB45wfpVSy0rxLcxaddvLJMkkLRtbx4URALgLg8KT8pDcY5yBWylb47fP0O9QpTi3KS00172/r8jsNPvNO1OT7JdyRRPIcGGTgyAc8ckVs6wjNHFp1lBJGLxTELmBRiEKMjd7da5OXS5nlhtorCE30CJMUabaVDIcnODkhgRke1W7CK5stPN0JzaiTYVjeb5mZlBx83fJxjvWEoxbumebUoxupRl8vyeg/xBp+tQ2Czid5bvz3VTAhJCNydzE5VeMcYx8vXByvgB9QEl1Pd3MrWRdVC3CnczbdxKj+DJbPOT0qzpniK9E6rdpuTCgq6eW4PcnPGOn61d13xBZwWjrE4e6QLIIl5YjPPA69Dx3xip5Zr3LXuKdSr7P2EoJ36o0L+W0mRkzKk0jMEflsEjGdp47cZGKyLy6s7p0VUaFUkUIFLA7zlR07ds9vat3QNQt9VtVmSJNyOVwy8gjIyPYg9ffHrRrOlLMgntz5VzGrbCO+exH5VmnyuzOCFSMJckrr5lTQ3ujFJDcuJArZSQnduXuD71Q1CJtJvJL+O+METLsKOf3S5zyfTnv/jip4be81HQ4vsF0ttcxIsciREMoZRyucZHbnGQMVlveakUv7TXoIVtUXakkKtgAJuJYtgMO3A6nFXFe8/yOinDmlJprzRc0aa41VVk1QSAhmi2OSFODwQvQg9c109xZwzWzW7oPJdGUrnGQfT04rgLe9SeVBZvK0Ec7xO2CArD04/lXeWFyXQBxkgdPalWi4u5ji4OLUo/d2OKvdOurSC4s3thOMbIJ5HOAnYsevAz09BWWVuo7S5u7fyoI1dvn2hhKgGFfnt16V6Zc2/nxGNiUBYdAMnnoc9jjFcz4gWLSLWefyDJbBPmQ5IHODkdxg1dOs5aW1OjD4r2jUbav8TK8JwXNmupXQKkIpdfMBClyM9eTj6Zqz4e1dtY1Nm1C3lifb5Yh5MYyMhueuRg+2cdaojX9QudNdRp8YsniIYzDC4PBH86twu934dkutIMcU/lKohIGUPQ9OvGcfSrnFu7ktXp6F1I815TVm9L32/rcnuYNI07W4Z7OFftSZLhEycc5IY8cZPAPeuhj1G3eNWWVdpAIyy5/nS6dbRRafDENrqqgE4HJ7mozpNuSSFX/vmuaUoy3OGc41PibujzjU5AvkSqu8QGTe53bYsLkMce+M+30rCspA2lRWcv3p/3+6NiC2TkHDfMM8fma0zqd9BFe3Ubqq78oyjhgQMtnnOOeMVWtLdbS1tLaK3khMisQxO7LAn5gcccYOM9OMcCvQimtz6in7sLNf0rv8LliTU0MYZyIwpwZN2A3seetZN/FcTahFcLLHIpRo15x8+cbcewIzWvPZvDAboyOkjsC8UYGMr9eOfz5qJora4u7a4WOVZT+9C4O3JGOQenbj1rSDS1REXyu8SKOwFiJEDRhIyNig4wccj35q2su8xynLsse37vXtk/570PGy38sbwmZ5GJwDgIMZyfY5FUZbqeaCQxArImUCFSMEclj7c1S97cpNz3J+buaQsW+4AduQOCef1q7DAq+UiEouB8o6EY6VFDdRxiO1hXqm9z2OcYz+v4V0MdmscHKNIQQynv0/xrKc7aGFapayZzAhVLyUIrTLt2bEGCsnGBknA4z+dbGlac0cspl8qX5V+VkyQvDEN2z06U17cvK4J2FhgjtU1tiwgddrJAibmccsxHHpk8AY+lEpNqyJqybWjNqZTLGVAAYjPHQt0xk0+1sGaCHzAFIHzbW3c9Tzj1JrOuLtbu1iNu8ZeYgwTbNyq4+6WA/wA/pWrbXFyiwxztAJ2Ocjjp1x+tcslJI8+XNGOhUmis7u3nigMqPbv8zAfMhHYHvVKTRAJ0ngwSgy0fQkHsR+tbl1A6QyP8r7iGbccZ9uPSq9lbtC86Q3C7hhl8wcrnoT3ojNpXTHCs4q6ZkywzrHEbMKEPZgSPbFRQTFLlopoHSZeSwJx06jNaN7ZahNHse6QKpwViXlR/eUkcn2IIqW3CNYvJepIrohYnBY4wTx6nH/1q051bubKrprr6GXcyyLNiOcbSuVLR5B/HNV7jUY7Sxka73BSMvKqblB9Spzgc/hXRR2IaGJssbeQCTkYI9yD0rJ1XTvtNs/lMYbgjacKCfXuMfhTjOL0ZVOrTk+WRTaRcQ3lrc25SKMogVcIc4x82cj8Mik8VWkl4sV7psrRagR5ZkWQKspwCqtnv1AI9ajt5oUzHGihgctGc/j71NZ6jPPLI0SxRCMBQGHEo45JHTAzVuLTuuhtyyg+eHQq2EN/DpsqagkbMrl5SoaNwc5yOxyOeDjqPWrsckUQMc0nmQOQFdyCDuOMdeetdDqlsrWfl2szK8mFV8F1U4PUenY9K4rWYLMC2t7+f7KXlEaiMsEcjpx/DnPfuKmnJVDKnV9s23odEkIgbAh2B0J3RrhfYHJ54qjf3F1aXc0mwTWhTLbTjaO5BJ56dOKxYhqcBGnXt+8xlGFkjUcoBgnOcg8H1x7810NluXSoYLN1kiEYCylshsjA6n154/pTceXW9xSXI9WmVtKvZ7mFJprZzauC6gxlmXBxwR6jB6dKvw3ccio7yn7MuWkhK9Fx/46eM8VTXS5Gkt0F6Yz/rJFYEOwxg4OcAdOn9aJn+yXEMmlQJazSsI5I5OA0S5GVwCMY6DjP6UpKMnp/X9dyZOMnp/X9dy1JFO0/222mFxpjAFSB+8iPPLHngjHNXtP1ddk8F08v2bO0H5lYk45DDnv8ApVOz1uBI2lEkduwfYI2AU9MguDyM4I5/rSi8jNx9kEDrDLloiULAnbuIDdOx4PPBrNpvSSJa504yW33/APDm1Dp9tqkCXsvkrdhCsnl/MrDJ6g9fx5qnaaSkOnSxXk0ZErlc4C8E8Lzyf603Tbb7PqsU9sHjSQdc8qQM4Pt/nrXQXU1rMYjcReYUYug25w2CP5E1lKTjonocs5Spvli7p/h5HF32mxRCRoYIYokIuISqqdzcgg+h7ZA6H61NpV250f7RD/rmjDNECQEbHKngFeT3Faur3Gm3MkFu0xSdwSqbWRjjv09j1+lZNvCIDcSwAlZAHILHr075xxWqk5R946Yyc4e+nfzEur7UTe24MdvJ50YjkjyA+DwwR8g8Ak9K1bEWMljDEuntJbQxxrFJP8xLqSFUjBIwTkMARyemKxrrF7bwGKMlJBkIWI3Y9cfkatmW7STE0SCPPy4bgDH4e/FKUU1bYJU7xSWnzsatnoPmWPk3k7yXSSu5m2EZ3HOOeo57elZGt+G75Jo47D98kgLSSABdpGMdc888fSrC3usLZySWbRmVQR5bYKtzjOTjoBk1uaNqO6ztlvpM3jD94GAADYyRx27Co5pwfMmmYOdal79012OX025n0HUHtpradY5wSm1fkXGOn1z+eTWzpnieV2kt9Tt/J2LuE4b5G5wASe/149637u0t7oASpu252kjpmud1XRySsyXGxncxqjMXDEk4w3bP4/WhThU+JakKpRxHxqzMbRlfRtSvr22uYWtN7IbZW2hnyfl579MEdc+lXPEb3OvRiOzIFm48qRI5CHRwwySy+mOn1qC9jukgeC8QOjDlJOQfqe9XdD1R7JXjvYojC7FkKptwMfxepznmtZX/AIi1aOmcH/FjrJHPeHNMu7fRks737HtszysTFwpXgH1B6E9e9btx4mGkrEzQNPkIPMDbVbOeF9Tx0+lbljrGkXt3MlrPF9pU4c7dp49yOakurddoXfGVkOFBxycE8Z+hP4VnKrzS/eR/QwlWUpNVY28tiWy1e2vdOW8tyzIybwgB3/Tb69qr63I01nCUhO2XhzIdpQEdceuccVj75YLhJPJ8mQHB3OB8vqCMg/Q1PcX8y6isrC4ntXiETIjLsHOTIeM7u3B7dKz9nZ3RkqHJJSjqcs1vd2k32ZPngwwAbrGCMnB9zj8qk03TLx5bURsbW/hG5JmUlGXHKE9COMkH271q3VnFIzwsHkjmdVjdMfKSeCeRwMc854qp4ot9ahsktlEkkf8AAsX3CR2ZgQdu3I5z1rq9pfRPc9GM1NqN0r9/6+8tprjadcXEd3KtvGkihnPMRLHA9xyCD6Vu/br3tHbMOx8zrXkmsaXrsuoXN1FaRR2pXywqxgOhKYQMSnXLLz0Hbmq9x4vvrW4lt7iwgM0LGN99y27cDg5wcZzU/V/afDZm88qVWzpWk7a+W3mdLbwD7B5cCtGEclYywIxk9OeBz0rOdkN2iTSSEg5KclB12knnAz3HP16Vs2cCjbIJN7YZWXJAIPt+Vcf4ylm05JzZQRPCVDXDsmXP8PPTg8/T9K3h70mjrw69rNw6s6B/Ons13SBDL8/lk4ZCAex9cdMe1XbItJaRmQwxNkhyMk+w9c4A7Uyxlt72xtb0QiVNqkSI5OR+JyaSKTbGQDHJcRuRJ5IP1A59iPx+tTe6sYSd/ctaxLdCdo7qeQqsyspVgRkoCO3uf5Vis0kkdyIGG8fuyQPXGf0NdL9kN1CJ0UrIq8oBgHpyRXOX1u9pqnzqF81NrjplgBg/lWlJp3RVBp3iWLeAvdW4UgqqKXJ53HI//V+FbupSmXTYIo2kXfcojFeuN2OvbGPris6wjhlVZlGJRtRyD1xyP51flmmjtpJLcIdpZ1BOF3Kc8nsMZrObu15GNf3mvIW6dYIHmP7wCPO/byeKpWl7e3drbXFkiMuAWVupyOg9T0qNNXh1SWWxk3mRoySfLwMjhh19x9cjFQ6VdSaXJFDAoaIfKVX+704zVKDUWmtRxg3F6anWaIIr6w+VEiKSNlFG0FlbGePpnmo7hY4HiitYgdrl8HPyEkknJ/p61btgVup32r8+0BuBuXH9M0XKMLiINbuQ5O51HA+uD3+neuTm97yPO5vfb6FmG9gnL+Vdwkgfd3AkfUZqncXDtBJNHYxR3MiKGZpAGGGOMkZ6Akiq80MSNKLGK3Eygl84Ukf8B5qqtm75M8u0XC7SqOSnpjnpTjGO4Rpx3v8A18izcTTRsk1wrFI+Q0A5YY/u98jA7/hVnTb22u932a48zaAXxkk+n8u1VY3NoY4jbM6hAof8Ocnv2pk1zcG8HlxlHGUaEhSrgjg5z0z/AD6U2uZWKcbqxq2Hm2yvBNMZtjAiV23MwPPPpUOomaQefZRrMVBBjGAZPXDZx+f5iqEiTSQ/6PCITDljbu2AzcYyew61bgjYXLSGd2jkRd0ZbdtwcZUduoz+FS1Z3IcbPmKdxZWkmpPCkqtcCLzTCOQnP3s/wn8efeqsii1TdKm4ZCjI6H0OPX9a27HSrexnkkso0jkcnzWOcv6c+3vTIwFjaCdtyIDuLHezZOR0HTHr7VSqdtTWNa2id0VIpvJKJcSsEYbggjIG0Yx8wPPJqrqtxb3USW95EiysScIM9G+VgSOvGeau32n+Z8sRjdVwdu7d15rN1K3mMbbm/eDLKHUbfpwPrVQ5W0zSmoSadyrqd3apqiWccH2SQusit8rDexUHKEjqG68H0zTr2NYRIkdwRKjlGilAaNuMjPBCr0+bHb1qC3DpdLJIu87NxIGR24HOat3At9SYC8tlO5skqemOoOeoOBkd8Vrblsayp8tkthdF1KO7sUhkscXMPWLzVJXJONpz6enarkwS905owiwSrIwiPmEEfMRkHtkc+nNY2oaZcxW015Dsma3m81oom+Y4XAZAfuk/3ehyfpU4McsDPNbxfugZWnU/LHJkg9TlcYGemaTUW+aJm4xeqZYv7Synhe2vU3agI8ecIgzZ243rnv06d6itI5rXR5dO127lmjY7ob5VCgIeFztUbCCB9MjNWPtKXFruZVVYxmcswwnOc89B7+lXobc2cKGMgwbmdlClxICPbp9f071Ldlyv+vTsK9t3/Xl/kZtrPPpF2bK+mdxMoeO4C9OfmDEk9yMfXFaN1FHcsJI5Y0Y9VJxUN8sd1A1yyiWCJSxiLHO8Hcu0+ufX1rLmsE1KWzuJ44442GDGHHEnqGGD35x6ULX3no+pSak+ZuzNbT7aZJSyy716Ng5wPTFaE8SoR5pOGU/N61mNa3NvbxiBokmwC2QwEhHU9evTnmrs948NkFu0dwG2tIo5A9T7VnJXd0ZTvJpoUxJOiNEBGduQo6Zzzj/Peuf1MXMt/HGLgxhmygWRYzJJkYUkg8fQdq2IpgkqqrqY2T5G6jB6EelZur6b9qUXO7m2JniDZwHHTOOSOee/pVR913exrRspWlsdRp3h22trKaKCeSOWRvMeVWyQfxzx1/Wm6nH9hiklvZIRb4wWdwvbtn+WaPDOoSS7YDaRIpUOojG1VyOSf+BZHA7/AI1tarYQanYTWl0paORcHBwQexB7EGuaUpRl72p505yp1bVXdHOWTNiZ9MvGMGSSoYsAw44z071TZrq3dWsJBG8mWAKYXI68Dj1q3F4NNibcaVqEtpDEgV41jDec27JZu2TwMjnHeuck8RWKF3l3maJkjiN0vlu7Hqx25IHODkY9+uN4NSb5dfkd9KKqt+w95emvlc6iO6leNhM0KzSYWeeJRvGOBgEEHrjpjmp9Kj0u9eaKCZZUhREf93tO7ru3DAOcjgdKzbDVEvoJEeOI3Cgq6wtuK8kcjgjqOPfFQabb29tM1paSbXt1XzP4VOV6queB7DgVPLv0ZhKk0mn7r/r+kXdX0XTUl8qO4tFllZV2SSANJ2Pv05/wqrDpV/FfTadFdwbVQTR7XIkCHIBI+oPtVi+jYw4j8mKVgQj71DIexGQRUVvKLa6VZZHF4VAG4AEj0B79jgHjPvVKUuXe44zmo25r+pmao81vEIb1nFwFyrhlJ7gZyeBkYzVK61K8slsrdI7dpJQWednyE6ccZ9T6dK6W6d2nedWgG+MK6NGjbh6FjzxVS7nX7QrT26ThTgiFcDkDg4+taRntdHRCadk43KMt86QvIWjcDJKxMG3HHRenP+NbugavLr9mbYNcWk0H7uTzo1Yy8D5s4A9cgDucdjXO6pb290JIjZXcduU3Awy5YPkno2O3v7U6LSJbVDc2VyGEMeFjyy4GMDIz1FEowlHXRk1aUJxV9H0/rVG94jhuofJeyuLiAwEZZUBRmI6gc4/Lv34xi/8ACLy3P7+fyWll+d2WKLBJ5JGUzj60zTNdvpcLdMbl8gS7RtSTAPAzkY6E456c1eGq22P9Rqa/7ODx7VKjOHu2M+WtSXKt+6X9Mwjd7J2ELiYpIFkCsAyK3cj14zT20O2vYZ5Jg7NtZS0gODkhgM+gIH0rnsLcanc3VpcMLoHyZo1YgMuOcA4xgjI4Peuh0HVpbnSxDNA0MqckOAAzdDj8vyreSaV4+R6dSE6aUo7jrCG1sNJnSOdLdodzbYgXCsQODznuv51Pa6jaX1vBPGQQ5JLqQVyMDrXC6haalHq4c3+xh+8QPtYHaSuAoPQgc+oPNb2k2kNhar5QnePDkjCqmSSSdoXjHoOP0pOHW9zarhoRjz812/6Z1q38CGRWDRkqcFUZuvQ1j6/aO9nBNLO8sgI3EqARzxwPeksZ7y41GOCI+dA6lURVAweu7P6Yq8qOX8u6DIhVsoAODjg57d6hL2cro4VH2M00YJX7MZtj8Fhj/a5//XVmGSadbq3QsWQiVQMgtyDjI+lRX6GK58qdRGyjC4Oc8cH0q7pRVrjeQS20KSvGf88V0Sfu3OqdnDmEhy+o3MRhRY8BtwGGbIHX37fgKxrmWSzuAziSRWk7DlBXT+U6SZ8zEe/EgfjaKhvrVoVWaGEzxn5HVR1XpkjrgVEJpMwp1FHRm9pIS5swksp5I2jPYjj9aztFa58y4CSOwilZWj3Ahxxggk5Hv/k1Th+2xLCxzGJOFAbO3APPH0H51qaTGLX7QR5zsWJZ5MYIIDcY7ZJHPPH41hJcqfW5yTjy3e9xPs7yk3kiGLUDF5Yh34Q4OeuO/T+lJayhrpbNovLuWTJjA4XBH8R9cnHHY1mzPqN14itbXTrudLeBjLcvNHlHDYwitgZIHv3rRNoEv41mmklvJA5WdodyovGFIH14z70npo2Eo8iV3ur210/rfuRJcXi393FLBK0CgFS5746qR6d/wptzJOlk6m7T7QzkRu0fDAchSy4x0q3ayu9kbf7RGfs0uyV2hIJHoB/D1HIyKo3Kz38kcAd4FikWR5cbd6gnKEfryMGqVr7Akn0JNMv1eZlvZGlkljDxqYRsBHYOOG5qPTJ9TE00FwgkDMzSEL5bRoRwgx15zUQmtLAvBqd5BbCacLbiIH5jjqRzjk4z06c9qpQ3p0m3hhjmup4/tRkjvW+ZXGWzGWI45UjHpz0qrJ3st/60NFQcr8sd9u3yO1szDaWqLNcSOIlyC+WcKOufXpVG3t0uNSkuYnSS2VNxUgh1YjIxxxwenvWdo7veavLf3AuoLnhPs8hBVR3x9epPtW9NGgaddjq7jO5TjP8AkVzyXI99Wckoum2nuyFzZ2pMtziDzXG6QkIWYfdBIIz7cUkkcxvN/kQPbEHIfksvBG3/AD6UWs1leQmHyppYlyGEy5GPTnr16VO7I8LpD5BeFgEXkYPBwfSp2ZN2nruUbuyhRDLDGckcIRyv41mXiTSwzHyiGVx5ZD4LjPWtwu9zbzeZM0bLKUVli+nB3Ag9+af9lcr87ZfjIxtDfhzVxm47msKzj8Rz9xHFc2xikBEpTYzKCCCCSOQfqf61Qm85radbaTyZkQplU83ecHj1HXgV0L2qg75OCRyFGSD2PHNU7qAT/IHAdRneo27geQa1Uk9DphUjfQyrUy6XAkr2r+XdQoJLjAmQvjHzYwfxIA9+1dM1tFc2aBJnSJtrrJGcZPtz/wDrrLhmms4BE0hCHCkqmemB93pjFWb+5XbEiskccbecGZmRVCcncR069D1ANKd29DOrzSldDoRbW7y2km1ZJCGLPGF3nGD7N0H6cCqmoxrK8ToPPjRWPyYw4OO2eG44JB/Wor+W6ubkxTwYt3I8qVB8uQM7s5wTnAwQOlT2Vkq2pDzM+W5kHTIJABU/iP5ULT3mwta0m9yO0a8u5YJLmIkMW2vExHlDIwHGeTx1xxmta+djYzknyJRkAx5lOAfYc9uPfr3rImhmh1mOS0kVpPL4XHKn35yRj61ZvNRtYYmR/wDR7uY+YfLHVsAFifwA5olHmasTKN2rbFqXSvPiW+s5ZHi8tQvOVkz6L1BB4/8A1VDbPubyCCkhJIzxzjp+PFR2Gpraxx215EHjuG3pPtJj83AOdpJKnIyBn6c1S1EXMIiMV9HNKiRsbufaokYkgq237vbBI9snrSSlfll8ioRlK8ZP0/r8y48irdQxwm/iED5LxsELEfMF5wpUDOck+nJxjsdInM9rH5s4lnMaSuBjC7h2xnjIPc/U15xeX41GRLLVMO1u5LLA/DNjOCV5BHByKveC76/0t5bC6ltfsxj86NNzkxMcfIpOSwznOehPeoq0ny+YYnCudG/Vfj6P9Px6Ho+QOTTHhjcHeiNnrkZribPxXfLqLQajFHbMxPlRMh/e4PRJN2C3HAKrnIrr9MvY9Rso7qFZFR8gLIpVgQSCCDyOQa5505Q1Z5dbDVKGsine+HdMvL77ZcWqNcAbVcZUgZJ7H1Ofy9KzJPDFxM7PJflCF8tVjXGUAOzJ6ggkE9c7R2rqScUUlUktmKGKqxVlL9Th4dMurBba5vrOG6lYIkksUYEoJyOqjDY9cAYaseDXIdTkEd1ZNGwOx1bOYyc5+bAzgAZxz97g4r1A9DnOKw/7BsobxLqEMkijG5WILcjOSOTnHOev5mtoVlq5LU7KWMhK7qx16WOevGvdOu1t1tLdrNYCYYomLSOVHIAPoP8ACqIhmt5J1VpMxxs0kCw7ZXckYbkY/hfkcHt0r0IyxyqB85IOMDGTxWL4r0+HVIPLEkkcsmIhNEpLKMhscEfL8vUnHNVCtfRoKOJTajJW7vc4tLzUba4tIpdPlCThA2/LyKe+SowPTHGefpXRyR3McwZI08tsAZUhWHJz35qnaXyPcSrMiTGKE/uRKFkZxwQoyeP+BY9zXaQvaTwrGzxyqeiuQefpTqzatoaYmu4Ne76nGveIxeOa0jgXO9mUja/HJwO9QxXemeWmQw4HBUcfzrp7+bSbW9S1uLYK7qCG8k7ME/3gMDoaopZeGyoKS2e0jj95nj65o5k1qmZe3ils0eV+Hb+Tebm+W4QEqgSUlkGTjhm6jGG56YNdLLYJLOpluAISNylBg9OMN26Vm+FZrC3tTpTmHyVAYOc7Zic5wDnB+U5HWuihgieNJEDgZztPG0dMY9Oa6JNxfY9vE1V7R2VjHmsVgFwqXDNOwKguAyoT0IHakDx2VpNHtkm3AEKmOc4xtyQAOTxWqqRrujYDG0KPlxn+nHNZmqWjW1yZvOUAIiL5jEeWeVyPXqOD+dNSu7MmE09JMx7C9uRrluYbsxwOiOqq4BBwMls9T8zALycr0HfrJ73fZv8AapXnussjM0ezeOcdOhHArl20W21iMW2oCaG9bLowUFRt7q+OM+/0rV8P3MdncSaZcXa3DSr5kaGJlYDvnsee496c0t+q/rc1xEadT3o7rpbp69R93BFq2l289pFJEY2K7Wz0Q9Oeo4P+RTrdvsDStID5agsc9uO/6/nXS29rHNZSbUaPC53Sc/hwe2K4d1mlhkinlLFg4PbAJPH4dKKT5049DCjNVbwWyOjtJYdQiKjDB1LMOfTtV+EJBZ3E9sd87RAooPGB6fif1rmvDKPaRlHcERqcMeMYH+FbWgWypNBeHKs6Nly2fl9PoOTUVYqN9dDDEQ5W7PQr6hDcm6iSIlULoxKnuGBII+gIrRgklcFYHjYBxvSRiABnBx7jk055hPFFKmPLHzLtGOD3xVEXVvFdSF8ATFQUJ65OPyzmlrJWsRrKNrG40ptprdUdRLcnaglJOTjJAx6AGqyaZYfbLpkBF8cfaQkzDAbocZ4J2j8quM4l8lbPyiqfJIpOCny9P5d6lWNE82VgNxXa7ZxvGOM/571hzNLQ5OZx9f8AgmPPenZcxBoJQp2w7Qx2HBA347ZB5q3bsbzS7OQrGZ8LvVeQvHIOevORWTrljJBOklrZ3FysoIKg4Rcgckbhxx1571r6TCrQWrJ5kCFMG3k56j155696uSiopo0lyqKlE4jXrTSrY3N9JBJcxNuk5bckbAgFeeFJBGB3rL0uRrnSZpll+zBJEaOw8nCdmDNhTuU4xu9TjIzXdajo9o2QIbd1uHH2gEcNjocHjNed332vStdi36kETcY4okd4kiB3qGLg4O3GeTmt4y542WrPbwVSNWHKnqu/5dfvOpbUVfV7N9N1PTbeaQLFeQTOwXzM5Zoz0ZiG5Ud8da6Sa4ePUS1+gt7dCE3GYEBv4SAPUA98+1eJ6lCkWrlTdTT6r5pLSykpHIuAcZPIyCePce1d74bFwvkx37SG9uyY5LSbMcc8RVmIX7wPJ5GAR7E1hJWin/X9epWMy+MIRmn0+f8Aw3mzrre/Zb0oQtursyR5U/OQeuQcAEdOf8KsXDRJ+/urZ5FDg70Uh09Ccc8fyrjtPju01ZlYSS2uyNwhmyY32AkfODkqWHTHbIzWjLqGsWUMsWm2cE7STAmWUkYBPHA5PAwewznJquRO1meVWwvLL3Xfbrbc65723jjUAgeaSEDvgZxkcURXccsCwXDrHc7cugkyRjGcHv2rGttbgudLluEha5uIwhkit8EhyOcFiAfX1rWfzGuLeSOzVxjl/uOuRyD+nesXC2jOKVPldmrMEZUt5GBnmEJO7aM7z1wMdetVr9CoDKQiSAEBztKnHA/T+lX5rhYAu8IIQhaQYOQMcYFDyxNaoUR7kNjKlc4UngkH9e9JNp3FGTi72OePyXDedlkYZUqcMPw6EdKbZGMy+aXbGTjHJx2IB/Ue1bNzapOgZpVUOQIhs2Yz/Cfcke3Wsy5ja3IjTarqdy5YbgPpW8Z8ysdcKimrdRv20xWckcO5n5YI5+Rj1xnsKpR2t4we4tbqaKaRc5kZQVA52/d+ZevYkZyD2qaOEs4FwiPwxKnvkHGD1/8A10pgQQmKMExsFYA5Pbpnr+NVZLY05YrRGZBfCyvWN0vmMx/cOi7X6AMVU9gSOnPPTir8vlXUkSwPEJ45j88q7S4GM49RVhzb/YzBfK3lopkEmPnA/wBlh1PHSqcmlwiKzkuGZbbyd6STXIBibttIPHDYyOPXjFVzK+u5N1fXRmlqWIdOmWG5ZfP4jeNQxX8fT/PFUbOX7J5D34Ny1wqRLwN288jK/hnBPHXrT4ZoBqi2V1CrSyEywbEbHGcqe24c/X8qs6hC7xeZbrFKp+WVSSGbGcHPZgajZcr6kLT3X1G3dnpEE8Hn2dzeFoQu5WZizA8Y54Y465FaxsYPtFlHZPM3mszB/K3rHtGcMwOF9B6mubsbT7H8kJvUhnxkPKzvE5OAVbrg+vbHPU46PSr+3k+zrBdLBtYb5IlVhKFP3G4OO44PFTUTS0dyKvPbRt/18ye40PyUhAkRn3K0kjpu3EcHC54H5/jWfp+s6pBYypcQmYySSCGeMIU3BSdpCsOdwZe2T6ZrqtSGLVpAMlefw71zYsrlGaUTqqCUuC0SsUXjheOBkA+vFc8Zcy9456FVVIP2ln6j9N1S8fXPJN3Hc2ohdmQAB0k3g7GwT91SBn+dbSa1Zs06tIE8gkSs/wAqqcZxk8dCPzrh/FTatpiB9MMr3Mkwk2QoZEZQAuAAMD72Tnr+FQQf25q1tIGlgaKQASBUAiZQc42MTkk7lODgqQQav2SklI6Xg4VYqo2kvu/Q3vEfjOK2sJ59MQ3Agi8538tiF+YDb2AODk5IwOcGuUb4i4sLn7dGkgZQUSOXkZ4I3YwWA+bHHU+nOonh9YLbVLeBZ4La4bzvKlxt6DLqQAw44AyccdagstJ0GTy1l0iOURHzY4hltp2quWB5GcDIOeRWkI00trnVQhgqcbODlrv16fr2MX/hJp7TUYIdFSZWkjVwk0eGmyuAWyQO/Y/wkVJdaN4u1KL/AE7Wktrd2chYyxfdlVKEYGQME5AOBnrXQ3r7hbXWnusMYcb4BHh1wvGPcfyNFzP9rnjlS5fykzmPec59CCTke1aXlo1p+LNFiFC0qUEn1bV3+RUgjZJYU1qGOe5RFVLuGQuJIwSMk7gNxXnJ5GR1q7dWuhq1rZ38V88ihpI75w6spJPHmrjH06VlXOq280rRvYwsq5JwzdB6DoOlXNJ1BLh1gtbk/ZniyfOAKgccDsf/AK9N05JX1RnUpz+J3Xo7fdv9x0VtpmnzwutrczODtIbzvNK/99Z64755zSnRF/huW29vkX/Csm/l8qG2XTFsLdQDviAODgYAGMAdfSo1u7sgECAD/ruw/TdWKhJ6pnEqdR6833nGxWDtZahDdSA38QDtleGVXwxU46jr+XStXwnfszyREXDxS/vFlZSVK+xP9cVkSILS+gstXuri4aApcW9yFDRhS4ZSx4I+6BnB6nmtDw7Z6hp9w7O0AsZwssP7zzFIzkgEHoOQDXVKSkmmz16sbU3zddu3y/Ox0rxYcSEKATnngZqpcxwyRTGFA0m7c+D83B/PoAKaZ44G82WN9oyRGhyu4k847k/XsKqahareNFNb3EcLwkOvVtx7ZwRWcY66nLBa7lmzR1uhJb5MQXB3E8ZHTPen3MMMchmZFVowfnUZwDnI9cVnWy3NvePNhUeZ/mMa4DdNu4HnOABn69a2VnitndZ2VuBkMeT6H8ack0y53TuhLG8ikZkikMUioMbs4K4znGOR61lXUf2fV9zJ+4uAZeTwT0NWJ7gW94ZvMD28h3kthfLjxgt78g8VPqccF1pZntXjcKgMbRrneD059qI+6/Jij7kr9GZflGBJREVkWVmIwMdQo/pW9pdyojt9+07othTpt68VgaL53mNBNs655PA960bMpJcTzwlcLKwI29WBPSrqK6sy68U7xZZ85rqCYogi3QsFU9sfdqNNNSWaOZ5CJCkfmkcg45xjvyxpmmXmQzSuqONythePYfkK0LaULDMrHJ3AEjt7f59KiV46IxleDaQ2ezlkvIxBJ5Sna7MoG4vxhvfABGP/AK1dHcwma2ZHPUYJHBz61kwxiWWS4QlcqEUk9MZ/XmrkMVwzxtLN80YIfb9xuR1Fc83e2uxw1Xe3kV7m2gjsIrPcJlaQIx3EkHtgjpyKjnci7KW0zFoPvw9AwI4PPX14q/Y24hiInJd2kyGZcn2+o96bayQyebCJPPuIicMV59cGlzfMXNv1IEsIPsMogySWJYZJO49eD6+lee+PPD0kug2llb+fc6ig2QIvKyBSeeTkNj3xwOK7u4ubm3VFs7NZpHPmOhYKwHcnjBPbFZ2q6YZbe8umZDFKeQ+7IXjcAAevX860g5J3udeEryo1FJvS5x/guDU9G1aOPULW5tYViPmNIgdZZIlzkMfuAjI3Zq345hg0/X7f/iZWtnFFh0DzM7AswONvKqwAxk8EfThuhWEKpqEtgzznassMfIkaLZjAyPwAH945HaqGt3elXmtWN/JAl/L5Mizl41TzWGdpC7uchgBkZ9eadSL9pf7/ALv6R7cH7XE+0Wumtl1t5/drf/LBsvGC2upTWdzHDJo25VdD+8C7fl3RnK4ZvUcnd61076pqdzZG68NPFcWouHA89NswRvujOQCMknI+7xnNeT68mmHxrpNtrZFr4eR/tl1KyllkYDKwbhxlmB79GHORXS6B4ss4dd1truEw6XbWX2m6vIQoMLy/KqBST13PgD644FTOVr26fiViMRh3VnaNuXlWuzbXb063Op064ntbiB4JC88Tf62KbzY2KqAdysVyRlB/ETx7Z3tD8e2S6VOl5eTXN+zMIwttlh2UFRgH65FcNHr1jp9qNN02FJ7GVo7tJr6N9yvtUgoVw3TH8I6n2rU1CX7bZLDd6bJ/btmm+SS2HyzI4ZvMOwYOBs5Oc7q05lL4lp+P9X3KrYKnWSc46PZ6bd9el9+x6q1tci7kleYmHHmINgcEnHQ9hwfz9qeklzCkEdpZuFLgu2PujdyNrEHkcgjivG7PU9b8OXEiAMlzJIIDaSMxDNxkhc9QTgspx7V02meK44dVkaW4ME9yVRkkdjgjjcpbjBOBt4Ix3o9i5fC7nkV8rq048yakvL+v8z0v7cr34tRCSmARNkbGOTx14PH8qW/01NQtnQ5V1OUdDhgT71maWIXvGa/MLzptRZDHhiDk5Izj0x9K1FEdnEGe7LK7tjzSCRnoB07n3rmkuVrl3PIkvZtcr1Me+t3iTEavEYSGWVgCMde3aoHYrsmikVomAZcjdxnj29607G5OpyFhcqFiyskKKGXJ6HP4fzyKbeWbJ5ZYLtPDELjH4VopW0kbxq292W54N478V3w+IenSWk95H4d0XU4tPuxaqzNe3DKXkjVBy2Am3HZmHrkdz8NfGNx4w0vUL2XR206xS6a1hkeTe0uBk44xxwCORzjPFdJq9hNqGk3umvfy2oulaI3EGN8YYbSR15x39u1eP+L/AAFd2+tWun6ZBeTaTaWCWGlmC3+0JDMT+8lkRSGRmZt/mqTjnORxSfMn3Rzz9rSk535ket3unPqYgnje7int5DtlhKrg84bDcHgnp16VY1J7jRhFDKgkiZmfzkCDAzuwF4yTyP1rymX4iahpnhyR/wCx5dUsLYrpA1E3QU3t+sYDbYuHKGQfeBzg9OoHp2mXkesNNplxatBf2cMZuhGnmRJKw+ZFlYbWIIII4I96v2idl0OiOJhJpdPT9f6Re07WodVtRdaWd6LJtZXBVslVJA7dMevNQ6lpnl3I1DTM219sLvEFPlT9cbsdGHqOT71jSala6HGkciXEX2aUW5eSP/XA4O7CZDNxnoCB9a37i9tr+wW4hczopLkxucrj+JSOvWrcHFqUVoa8ri1y7EUuvvqdjLa34mtkzsaZXKhhgEEMMcEnAPfaa20u7iCS3DNEbdnI8wliSmOOf73T2xmueA2z29yl0zRMSS4AeOReuD12nAHIxWhGWsF+eVJLUELg8bQRj/J/SonCOyRMqcbcqX9f5mpq8bQRRvE7ywvOkphKBiMc/KDjHIB6np9aj0eytYryKe7aUXdxK58jzGaMMw3YGeMYXPpkmnQ3Uc4WFJlYkZjZPmK/4Gsm3jlhNzD9tuZQS7SnY8YV8YyjEcc88EisoxdrbHOoy5XC9i54u1RB59rPDcLsdMFNy7wSTlSB6gA9Bz1rBnuGt9VUWULRpMoiDg4y3LdDyeM8gj6ene2skGt6GjxzFopkHzqOvP8A9auJnt0hmuE/1ZIbbsAwcn269aui1Zxa2NsJOMounazX9X+8Zao0/mGDKzW8uSZVPpglT9OKY9rBLYyDysShs7uc/wCetOVbieNVvMPbpGylG/iBxwevOP0qWZ3O8wXCRrwzMFDDA9unPrW2t9Dqu4y3KEsaLAoIzKT8pztOPc98CppIYYJIJY7YgbOV5JUjjPsKbaxhrtNy8gEmR8DB7AevT0p0kkscrCX51wBhevHTFX1saXu7JlvexiSURbCcJ+94BX8O+BUCy2gADwIzDqS+MmlhuneNkZFEcgwHxkjPsehBz7cCkjstKCKJPsruANzPD8xPcnHeotbcxfu7p/Ix720Fyhtbu3jmtjvwSSksRx/A3O36dOOlY0k95o09hazzC70qSTNvdIgVrYkgMjIvB65I75yOeu9c6wl5ErPZTGQsVM8anaeSAxHBDc/1rMsr6SGVvtsG+GbNvdo7YIjPB5Xk8fMD2x71ooSavb+v6/4J2UqskuWcbrt+q7P8+pLF4ggEFxZyuW1WOQpgE7W5ODn+7gfUVes1s5oI3to0aLehVkJ3gk5DYzyp7+1Y0Xh27a6kmtr9b6xjBEEjOJHHXLdc9Tk+5PGMVpaEyQXbWM4E0qwrunA4bOeMenXFP3XFuIVY04/wpXLs0jyXpjkUqABu3Nxn/A07WHhWIWbwxRu0ZDeYwDKgOARnhvz/AMKdqcUFsUkuFMUaoV3Jl/l4HQZJrpbbTtO1vw7bRur3MIH7t3TDj5ueuCOR0/8ArVjOajyyexhUqxpqM2tP6/qxyOmX1jdXsEcsM8Uc7NHA7HAwc5HHI9eevFbKxRWwMGwu8BPJyfMUe3f+dZviLSl0zUIHUl4yoWNZG+UuPun68dvf2o0meOOyTc5aSMnJ3lsN3G72NVJKS5o7DklOKnDZkOowrBfRXYRtmCxyMDB4I/lViFfsKTFVGx5BtXpjccZ/WpmuPtenylyqsvysrHBRucHr0Pr0plgRfwlblyJIEyB3IX19etVd8uvQrmbjr03LEemh7qORWATcCyY7kYyasrFtS4WQAkS4I9BzRGskssLIW3hCzRlCFYdsn6YqTyS0tw5JG4YKkemKybb3Zzubbs2QWsztp8ifNlSd23qSPT8a1L1ori3SP7RLbytgqy4BIx7gjFZdrGySiCV1VCu8Lt+bluuc9KtW4cPOzbXMajytxC8+n50ppXuZ1Ipu6NZ5Tb24Nw+9iQojTjnpjP1rOecGwmku4bmwUZeR42AIUc8Ec/lU+mCO3ihhLSb3BIXkkt1Yk/jWlBCkJbyxkStuY9umP6CsbqLOVtRe39f16mVbXaGPEErzSgE4bGWB54PSo3iN1dRBxbHT9ofZMPnEmevX/OKnv7BJI3lCyQOvBaLuO2PTtUMZVDafaZgIonLgKCN555OPr0NWrbxNFa14mFr9jaX0V3ZadPDBeBwZXiOGbOCOhHoPyrnrjwvHLpMmnrO91P5nnxbZPNdgyn5iCcAlu4HHGc8mupnsbW2lLj97cCRp4lZtuQT0Y4zjPNS2lkL8Q3S7bSdmEjsvDHHGDxnpWt7R0eh6FLFzoxSi9Fr8zyXxJY31rcRJJaBFjhiIhUb/ADEA4Ljox2jkEdF9OuLeeHYdc1PU7nUZb+K3lu4bvUoo2ASYIpPlmPswGRnIwM5HavY9V0NbjQrvbcypCpcxPKrMSGPRcfOF52nPQZNeb3+lx2MG64XdBIAZQdrMPmOBuHcgY7gcgj0VlU07Hs054bMKXJVirrTrf799ul+upx8+n6nqWtadfi5e21/WdUa4Co+6GysYlON6r8vCqx28HAFbHh3xvqc9pa3WsXt1fyXlxPbW0VtHK00tvFt3TIqEsFOGBzkfI1V9Lu7mO9lXJRJ12NDv+WRDkYO4EEbSRgj0p1/4cmvYrN4o7cXVpALBLM2plWOEsrrhVwyNuJO9Tn5zgdazlTcHdHJiMsxOCfNhpKS7Pz/q+luiO507VbbxdCZ9LsnvpUjaYJNKSPLLr8+4c7zyWxjIyB0rdW107Up7dPEFrbrDcxPBBcWzpvTy2y2eScD5jntznIxXiV9pl/plneXOmyT2t9HLFoWi29lMyOw3EyM65ZsMzfdf1x2Feq+H9T1OLVJNFEltqdlGrvM7wqFkmZcu+ducBuncg0o3l8OlvX8yKVapW5oKPK4K+79HZvz2T3W7LMfiC1i1ltOn1Ga4WItDHMUUSoM8ESKTuGPp29a6mxdJkgtzffaFhYFHnVWxyBjgZyMHBz161ysXh7R7i/OoLdWZRJHaS3gjWUqhLDKjg4yVGMA+hJxlsVzolhOEbzrzS7pn8iUM0ZU8BkcdVYHHJ9R+HQpRkra39Oo8Rh6dW3sU7pa6dfLZX/4c9MsJI9OEcLCZy53G4+9uYnqcdOSPb6Uk00cV88aNbJqdwQVVyzb0Xt6A4z0+vNc1ol1OfDEhtnvEtnc+Q2UaVF6g4HbPBH17V0gu1eG1vMQohAVnkcIyZ6Dng9ccYrGUOV33/r+tDw6lJwk7/wBf12LN1HLsTzFjOeGL8hOR/FVGWySK+JWUlim4R7fTr+daW2OaDdGSzISAW46HnqD3HpUbl57l4HjkMbJ/rAQNmRzhhzWcZNGcJtbHmV14J0iHWxrekWpi1O1aa4t7Yzv9k+1upxK0fOCCRyuOmea851jWNU8BaZLpME0kF7DGuq3mpecoOpXkv3lVHQ+aiZCbQytwWr6LvdLTl4CykAc5JPA6/WsK6sUlZFnhguIEcSr5iB1V1OQdrdwcEelXaM9Y6MqVCnVXNSfKypp1jcXljZ3OtW62l81tG12kfOxmUF42H8Q7YOf61HdaRcxalFdeH4I1icNcybGO2c/xKR0w3TGM+lbkC7zJJKWK+aof8c8/z/Omyyrayo0KsyfxJnGSO61spSWiOuLkvd3ZzFpfnQVdJGmngDGRlIAeED74PPPPXAHGeBitjTT50LSI5MEjZSOUZwO689unFVNcs7W708x28SxQsxO2GP5xIxADbhyCG79888ZrPt75La7tDcX80NpcBrffcR4VJVXhS3TOP4snJB/DW3Om+pq4prmsaJmOhvMLqJ/343QylM5k3HAPcNgD2J9OlaOh6mL+5ubSe3knWQmNWjUjCJkfM2f7ykDFRhjNpipfSvHvJSTY23PbrnoeDx6Vlz3v9kHaLzdtb5njiyYzk5wACcknkd88c4zHLzppLUylHnTS3O2h8QQWetx6ZIHzJHvVgysVAxyQDnByR07Vj3NuZb2WcXKoBMyANg8k8DjPX3rADwX+pvqVi88mqoqnYpA3LjBwr/cJz0yOmaluJo4y1xgxKJmbduZwF4JOR908gAH0xWapcr03MqVHll7nVfjYZGZPtYa4UsuQ4ynAOeCB0FWDYy2kBkt2dYZyZGCcBeOc475rVh0WV7SVoZYlLrhWYHd9WyeRz2xUU1shaOzmm8wxjIw+VJzwcA8eneq9om9DolWjOWnQq+WfsytcgMFxkKcHOc9O/vUrkJBvi8xAhAyTnHOBmrsUSvFtmZZsMWU5zt74OeTWM1y0d5Kto0DRKmGTBDr3wT34x2oj7wR10X/AHhzdrE7qwctuUoM4PuR0PWpzbEn5o3J7nZ1rKW8LNIJFXavY9vSpBrTgAGM5HX5q0cJdDWVKafuozvDWrEWtyY4JY40JCpGjD5x95RnqN2cfXmtWDfFfhrYWYF2wdopD8xA+/ge3A68Z6HpVO2urYPLIbSSBriTc7DG3ee+MZGdxNXhteS3e0ljWL5ldRjOT157dqmV7ttWuObjKbkla41bWzlnlwj2033mij/dgjPX/ACahtrK0SR5bZikSfIuVxjDnOR1656etLJF5yifcQ3zDdtxgA5/mB+VTQG4FvHKzqI1jJum2ZVlAJOMnjjrTbaW47WW49prW7sm/evGTuSOVl2rvGf0967jwtcySaLbefmSXaNxAPPvXF+H4tNvvLitGiFtg74Rja4Izn2616BpFnBbwBIQgUYwFFcuJcUuU83MHGK5HcqeLIYX0iUSRZBwMqdrKOmQfUZyK8tnFvp5E1p5/NzuZPM4lLDaSc+2Sa9T8WMP7MkjkKhJMJk8jPpXmUGmldKcZg2By8SKvBx3/AD/nWmEsoam2WW9k+Z9TRCTNJbJcI6eflCsYBAUEkFj6dKa1lJb7rixlUmIlJog2SueOafbrbLYwpM0kWwF8o24hjnKtn+EdQO1Pg3WU/medJNFKhEkYG8gZyCD3/wADWvM1sdPM4/1uWtF1OUWkwVFbccKS2OMfzzmrNxJOyhFbbuAII7gcc1m6cLaVC0EmIxk4P8Gc9eOnFMLMXuIldkdCGU/7OO3tS5U5OxLhFzbRcglS5uFYf6yJGXPqD1B/ECmtI00EiQySRS4I34yBycH8gKryMLfEwcLJLgY9SeD0qa2kV5gu5dwIBG7AIPt9KGuqG421RtaRJN9jP2lVYtIwVk7IO/1+laCTJb2se5MAkABFLYz3OOg965eR5bOWaaOZpYtp8uPA2q2COvUjrVnS7q+1Kxnhuo1CNGQkiPt3An06jH+evGM6d/e6HHUot+90OhliE0UyoxJK/Lh/x79/f3rl/DUUumvc/aGnQGUjY0gmBc9CBjPPoPqa0Y7ryNQSOO2MglI3ywrzuPB3e3A5q1eq4mdUTy45AjNLkZJzyuMelJXinF7MhJxTg9mUIrizuNXukujLuOIl+0IAhA5wh69RnmqlzcjTLyeOCCeO4OWiaST93L9CM7fxq7rNi195U9hdxo8LEozjeBkYOfyPepZWmnmQWNrDdW8jDzvMdAinIzjqScVaa0/ItSSt+RnahcSagYRcmPzRE6hopuY0YjJxgjcD7VDHoFlaaei6RBNM2P3ke4ogYZO4ehzj8625rPR7ZRZrDax3Bk83y42CsW5bPqehOKrlb640wSWycNHn90+Nw45GSO3PNCnpaOiKhVsrR0X4HmWuaRd30tlDNcvLIE80Mp3Zz/CTg5xgAEj1qSw06XT7gx6mHl2o3lS27vG6jZgmR8Zxxgdcc8V31hod0LL7Q0ZN06+W0pUJKozxyOOvesI2t3pYutRkjkv5oh5UlvK3ybsj5xkZHB6jr9a3vGd4o9SnmEnH2Sd0vkcVaae0d1K1j5pvnYpE8btIqncOQU+bdg7Rux1561a0e5+xWFxoVjYXKaizFvPjkGQ+AdwyFwvHPPGe/b0IaLpuu6dPcaCsX2+Ri7StId6Z6kY5z6AY+oq3aW1n4Yu1utWLm2SIBJZo8mJjj5B1JJJYnHyjpWPOvhtr2N55tCpFrlbl263W3qvI4Tw+vk3V6t3EguxAYDMqGVCzn7zqG6kZU8deSTUeoaTeRR6ElsjXUrwm5NtIysjhhyojz8o24XtyO/Br1G/13T7cxPqfkxWMpVYd1sW+bqOnTpx+XWsLxAlqJRqOiSRs6I0bTouAnBUBR0UdckDv3qVKUpXcf8v612OalmU51LuNr/NXtbf9Cj4QsNVsdOkm1GWO2ld1jgVgvK5ByevPJG3rkc881p6nMFvbdrUgPcShZ41YDzBggnB6kYyB7VhaRqpurtdN1uVbeJ/MuBgKVcbu5GMdz0FajW9pB4hnuI7zMCosRHJ8tj/Fnpgj8MitnBqV57nNXu6snO132WhteHFjSyWd4ozcRh443RSPMjzkHH61Z2zLCF1OWFFZsb4mZTng5GOnPH4Vl6haTwzW93a7biJCC1uIwwxjHyYxt68//WqwLwy332ezS3nheJXBDA4UHBDA859Dz0/PCS5nzL/hjilG75l/wxsyGK2aaUGWefYMpG2447EDOKpz27NmXY4efBIdsY4/ukdMVUmsbGW5lhMkIZj5sLFsupzkhRjgZA6c9amiWKKOHz1IaFjHkbpTjPByee49cVFrbbmaVtU9Sp9jFtMhmEgt2PzMv5jrQtswu/IuCrbpAA4HQEj88Vp6jY+fMjhmdTkMgxgeh/8A1VThi8ho9xyqsGBB4I61cZ3W5tGrzK99Snf2zNPNbxqxbeVLKdvGAQf896z3kijn8ye1hkj3MXtNinLsCCdx45B7+orXuZJG1JzGMEgNkEc/l3oa3hnjllDKCSN2f4ic8fpVp2SubKVkuYyp9Pu7O6fyl+16R1ktmO6aFcE/KT94Zx3OMeh4yrae3H2Z4YoYbe4O4KxzHKD936c4I/Gt54/sksV2CWdwUKFydqk9h0xnOe/pxXIahotldK02jQql5ZSO5iZyVdsAEAcgcL6E5HryNqTv8X9euv4mtNOV7/1/Xf8A4cl1PSRpj2Wo28MmyENjagMgJ6xuwByD2OO3J9ehsZE1KBY3ijt5I40R7fzBsXgEADgZGevB4rD8PahdHUVjW8EY851WKRg2fVTjr6j2/GotVsdRtZLVjb6bPIVMYO3C5AJA2k4znocdMjIzVyi2+WT1FJOUt9UdampKbhFhtd9uqeTHOynnB+bgnkcKAcdielM0q2aQtJMMzFmAYMuCAehI5xUNmkyWBv7+7tLcp81wCfkxyOOeOferU1xbW8MDQp++ZC+0dAo7545/pXM1bSJiv5Ydf6/4cr+VeRKcJtbcXLpjATJ46+nHHeo7j95bK5ZTcqcAD5GAwcc+vB7dqs29y91CvlmSL5yrKq53gDHfsc8dKS6jaa5iknDJKhOxIWUbx27Z6HtT1T1NbtPXcxijIyB4t6SE4cDBwR1z3pv9gzHlY5ip5B3H/GpJbH7RcTeYrqqOMJuwOO3H+fWtJGKoqrFLgDAw6/4Vq5uPws2nUcfhZz8NtaXt3FcwxzFpslo5ARsKnhge3QVp2+mK1xOPLEsMgPmYbnJx0/Clhktra0kZImh8sAgxxkZxx93r0q3aLayeZNaqu7crOASC3GRnsamU3YzlJrYiuPM+wx/Y1jdgNoOcquOCPyrV8NxN5CSWiL9nmUymUvvXecAfL6YHt/WuXvby50y2DugeLPCRx4DLnphe+CR6ZxXoXgu1EOhRJ5QiQZVEDbsKCQMn1xWNZ8sPmY4xulSu+rOZuPDWoPcaizw2dvpyqTbJbrs3A8HceMEjOT79eKuaZ4mt4PJSygndJF3yNvBVQBjKnv8ATv8AhXcSIHQq6hgQQQe9chc+ENOizFYL5ALGQKGOFJ7qM8duBgVlCrGatUOWni6ddOOIXpbb5/mbMtxDq+kROEbyZwGAOVI9MjtXm8RNtHPb26SyhZPlMg25BPbPTGK6DS9Wu4L1bHUii28e4BgmTL1CgkDHTB9QRg9ayNeukutQaO0k8uIAAkjh2bhTn1GD+lb0YODcem504WjKlKULab+QQ2ksuLdGkUGMqfmA3Mc5GeuQO/v7Yov9EmudOtF0t0Y2b7PKeX5kYA/IfXPHr+NV5ZJ7HTo4dr3LRKrFjk5298884FM0+J2s7cofs7xbtgKlVXORnacE8+2MVr726Z1tTvzJlH7S9ujwLBGX37SwyQwJwQeucc1ufMTHF+7iugC0XzcMPTnt/Ksa20e4i1Uu199ohKASq2B5ecnzFwfmAPHbqPrWgB5N0zP58rspijJjG1D1OCeRkfgSOKqdnsXUcZWcdyZHbVLHyVKxXAfOHx8uDyBipRbw+Q8wAjvVUbSG4Jzyv88UyxaMXEQZdnyhmIUAb88nPftx2rPvb62sIUt7tUtzLKUXy9zByxJB6ZGf51O7siLXdkadgVneaCdX2kc9OM1fsrgacyBEBiVdqj/A/wCetc9b3EsF6A53si5UkfeXpjPcirRn38sg8liQnH3T3zRKF35DnSvo9jpLe8F07Tm3NvKdx2uQWOBjOBTrm3eSe0lmm8ry/mIGck4wM+o5rlfsbLE9xCVN/EjRpIxyVGf5Ywa6DSbmMx7ZHDyIAeWA3d6ylT5dYnLUo8nvRY/N3dX9wjqrWUce+NI22GVjwQTnj8u9aOlWZRQ6xwJC2CEj4KnjOSOD0qt9hjmhLyHETD5iGPTvkjpU9lPb2FuyQK/kqTI7HLfU55PpWcndWic03dWgWbQH7fOHhkLDGJWUBcegPX/Jq25WRmhYgORuIUYwD74rKnubiV5BHMsEXDxNGQWcdwQw4PNJb6sZ4AsUc0E+F3+cpBXIycdifXB4NQ4N6mbpyeos07aVbsI4ZpYnflsDLOTj/P1qV45fNhSKxZY3JMjeaAE/Dv8AhUIle5vbiOG6t/KTGUClmVu+7t6YplxZKs4miu5FmY5cNO23BxnA5APAqlbrv8ykrb7/ADJdGt/IvDMFgjljZ49sRAVwxJyQOd2ev1PWql5A0FkZb67QR+ZvkVn8+MMT0y3IHt25qeyt9Nm2CaYlrcgo0w2uGxySw6n/ABxUtzo9nLYwW9raWT2/2hZnV+V4zyMd+nWndKWo3JRnd/l/mZ8ej2l3OLhtUZnf94YgdqAdiFOe2OnXFZMVyuhajLHqEZ+zso2zw7TGeTkhN3HXoBnvz215rSwEM2oyWb2TRB/Nd0+Z1BP8XXGRkc96oW1mb24iksJ5fsrMXzMBLHIMYK8H1HXn+lbRd78z0/rsbxldPmen9di/aW2m2889vcTmW1uFARZyGRicn5W6kn0zxgVLaf2bbaxBcQSKsLsYiFUsjsBj5jj5cYPPr1ofQpZnc6lNBPaBlaOBEKlcHkZ4IJ4wRjt70zUIUdoptOV5GnB8tZJCqbWA6cYJGB19TzWd09L7md1LS+/3G0biw097wvti+UyuCeCMcsB+FcxqRmXVUexzFKCBllDIUPXbxxnABx7HFJqNvdalY26ST/2fcA4lgkIJO0chT0IwRntUV080V1D9shWCEYeLajOXZTyfkyQeBx6E8HnFU6ajre7/AK+8dOmoa3uxbe2tIp7i31Uq6ku252XdGCPmbIwR1I4z0BzUllaXkF2bGW8M1m9v+6lOCyAfwtkYOQR26Dnnq+20VpFvp9Va0u72NlJRUaMYC5UZJ9cYPT8uMKW21OPULRjcTQIxZtu8yMjEMSMYGeMcYI6Y9a0XvXV/68jRe9ez/ryOyswlrN5MYja7cKHYYDMijAOMds/SlsVS1A026lnnlQ7RLPGF3554wMHHtWZqN4v9s6bFMhBvR5cLRlwQMZO4dFOe/X+VaCW81ncxl5mvI3kAlZ1yUA78Dr9cVzuOmvU55Lv1I7y3aC7LQhmUYGGHX2rPliYGSKQtsZgCG4xjpXUXkH2lE8uUFD94FcZ57Gufktr9ZJ5JxmMsVYqdxbA+Un0/WnTndamtGrzLXcrRxCQ7pinlgF1UZDZI9e/QVntDm7MZhCwhwcrwee4PqCcn8akaEpNbOSryvkSYJGAM4H61KiYu0jST5ChXJGQWyCPx5roWh2bJ6mDqWhrpuox6kLuOAyAxxcfu3OCQcdiME44579iWniS11O6e0vPtEf2dlheVGCbmJHYdPXIzx+Nb13aWtw4iuSZ4GXaysSFORzx0yD0PWsDW9Lijing05zFGHEscTEhnkGCMN0IwDke/TitIyUtJ79x/xLc2/fb+vmaUK3Gl2NwtzYxXMBw7iJ1ymWO1SOmeA2fXP0qS+lEkcElurLZXChkYrgjPVceo6H/9VcXZa/qWkWUYmVpdHKeTNExzNEzN06c9eDjknrXX6HOLi0awWRJY44EeGJ0CPGdgOGIPXnsvGe9E6bh7z/r/AIJlaVOV5Lr/AJfiizpUN/Laolru8iJg2X4BPcr79Kju5JVu44zbhHhADzHA39Se/bJ64NRag7210i3bGJNjfKjlmbJAyQOcA+ufwqCXVY0md7ssIpCVbeOuM8D8jwM5qVFt3NoxlKTlbT+vvNGe1Wd185ZSI/uoW+SXjv8AnW2PKUBQpUDgDf0rE0iWK5eeaGLyUCB5VmA2kDgEZOR8uDx/OjzJDylydnbHTFZSi27Poc8o+00vsQ6patfQxTCRlddrRPE4wwIGc+3A/KrKRIsKWZhD27KF256c55/GqUGoW15dMctkIwinBXB5HYE55wM4zxVu681yrxSMqFdrgAgkeoI6H0NOzVos1s1ZF7UbWRLPNspaUSBmITJAB5GMjtV2z1i70xoLeSJfI+WJUC4IyfvdeQPTrUH28wxJcM8nlL8hjMeCxCliw/vZ4/EGqN3JPcYmiBkDENbRzgblctkk47AHAx0A79axS5laSOZwc1yzWh0S+I4TezQGVlMgHlswGEOMY49+eay9O027XVbrUY9RmuCybFhL5jUZzwPU+vWsi+ghOoSYjdWxvLbTtIU9+OvJqO28221IzLLsWVF+WPGOM8j+VUqaSfJpcawkUr03a66lTX9VnnkjuWMMZRQsig5jVlbDEEc9iMU17dGf7V5kkJUB8oN25QehGPw4rS1BYjFLKYcsoMskcaDczEeg756/XNV1LtdOD58W2MfJtAUkjHX1+lbprl00O2DUYJRVjO+0STwh7YMxYhsOWUbc4OBjk1nzSpaWssvnzG5RlYvLl2UgAAjPUf8A16u6lZRzzAKZY3XhdkhUEn1x17f5zWpcaWbyITNADLbjzChbHmgDO0L0PrzV80Y2NJzhGzZj6Jdu9/BLe25Fz5cnlyyrtwuexxznjj2ra+0RxBHaUrGUJkWLDIgGTzzxyD0rM1TTm1Vob1GltUg2MEiTa4Yr0PTjBXA9iKxFuiLqeNrj9xESSkrLEitgnocZPGevf8jlVTVEuKqa3sbkrST6U9y1u7N95kiYlosnoAByOnIpby3kuLLTo9kvmGVi/nkiRE5PUA5wRwfQ81Hp2p3pKTXE8Vzhgqy2syAqM4zjqeM5BzyO1bF9reVu4plgNuYcpdoux1yPukBevXOD0+oqW5RdkjObnFpRV/RleERxxmOVVMSA+WXO8qR93kdMjPPXpTAzz24BcREZbaeh56/y/Oq9rqYto9PgezG9YVWWRE+QHkYHUZwPyq/LJFFbRPHafaFWQRyIymJ16cgHgjnPFDvF7Fc3LuivFfDyZYbtvs74Iy79D2yeRg+tIL6SGIJjJUfKG9fStNLyJYJfMtkNpD8rKybep2qVJHPOeQaRdOtNasPtmktLH5W4tHGM9OQNuMk/Sp547yWhKrQT95aE2magHtmhk4OOQzkqR+dWP7Wlt0aGOXBVSdgVTx9MVi/Y7rzwFlQEDLArjnA9Oh6VJc6DezKHWUiZBgliCMdcA5zn2IpONO+rE6dFyvJqzEbVxKxFwzI3TJPIPuOMdqrWk8zRlI55ZASQ83C7B+OcYqG7sb0zIkth9ouME4iIywHU8jtnvS2rNChY28sWP4GUhc45yO/1rZKNvdOnkp8vunUWyW0unRQWl+zS4XbI8mHlYcgtgdOnStS5RUFtHcXFuFEoQ+YeTnoo6c5IHNcLPeTXQ3XVtDLHEfkJhBHQcg5z+ZFaekzXJO57iQRNyYmGR7EZ5/XFYSove5wVMLJa3OsNvLHcTTM/nDjbEfmxz1HvTZ4LeKbzpCbaYqqloWPI5zwRgf59qzDeO6su9kLKV8xCFYfjj2q/ZaipCmWcptPRlDBl9OBxWDhJHJKnOOo68sZ7mbdHczQMpQBhKdsijqNucdz29KlnsyIFigYu6sGy7kEAnnBA9jxUrwx3Erzo7ThhgRhsoPpgEj/61SJGGd3if5G+8oIwT3z3H6fjWfMZc2xHG0wtyJLmNpXG1D2B5/z+FQxWl79gUNcCeRGO9mQpnnI9xQ9vGmqxStcTRzSKyhVfCS4HdTkZHXNWJXu0mlQQo+SoiUHDD1LZ7Z9Ofai/YG7bHLJLcSytZ6oGmntpF8mQA7wSOr4ADLz26963zpdveXSXRXZKkizEbSpL4K7gOxwSKp20l9FtTUIIo4WdvLZQSE4zhvxB54qzYXaS3zDlJg2Hhm746Mh/z68VrNveP4GtRv7OhrJDHMQ+7G07MLyG7EH1xUF5alo41hj3RZzlSAV/A/X61Ta8e31WWLfBDaOQz78KdxGevQk+taCpeR3Mk0Vwr2pAxH5YBHuDnnPHWsLNa3OdqUGnc5ly0etQiQu1y4aNI1RipTIJZ88Eg9PZjjvVvTrPyr2drFzA8khL27EsAckkgdiSST1rVS6MhVvIlVi+xgRyPc0y4up45pY4rUvcIm6MFtob8e1a87atY2c29Eixb3GbXM5CNHy7MNoHHv24pbR7a6iaWN2Rm+Vo2OQpH8qmZBLHtdA2Rlt3IPrVexsltlmKELGzFyoU8tgDOcn0FY6WZzvls3sczrFpJBMzrFuxwhxnqcZP581XhjWS5VixPHygnABxjNdOrRz3k1m9tJLhdxkP3VbPTrn9MdawdVt10+f9y4YH5ipU5H+PauunUv7r3PRo1udcj3K+GCqxHyFuOetZsxuWuY0SVFkjkL7Wi3KACQOfz+n0NWbO6hnxIDjY2Tnp+NDF7ieRtu2JGITjkj+8f8962V1udNmrpooSaNBcGyvRFDaXW4vJCW2+YO4ycjOO2fTpUdz4futP1mG4srdkhmhwrOynymPTABA2jpjJ/wAdW3K3EccN+qIG+cI4yUODz+XFXIrsNbtZI++2RgT50YcbfRT/AFHTFS5ziRUlUT3uZi3UWpRLp88xTUo1ZVZkMbDGM9RjuOPenNZ3sNj5clpvw3yyLlwh65yOnH86yX0+7Ej2N+jXgwZLW6fkkKclSQMhsDIXGTgYJ610egyC3tUka5aNcBGV+gHbj15HFVP3V7onLkTUXfy/y/4YxPtqxAMzHY/ySoqbwF91GWP5Hr6VoxRWU0aSrA+1wGGY2U4PPTHH0qvfaIZdR8y3V5Y2JnPlsOuACMAY55P+c03zJE+XY4xxjzE4/Sh2l8LNJLn1puxmapqMdhocdlr32V7+cAwRmJQqu2AwG3sM9jnmtG1lCaLJeWUcs8KLl7Nm3tECAAFKgkjOOvTOc8c5ugeHdNuWkutduZIogVtreOYYTcSSeckHkH6AV32heG00u9mlinhMMyBZYvLAz8pycjnk885rOrUpw93r+D9CMRWpU4tX132sn5I45jL5EbQeTsuVLxiYlxnB6dccdqqxw2up6gXuLeQ2UJWKOSM7QTkhlKj+H5QD06kVr6vpI0jXDbhg2l6gHkijCjYj4G9d3vy3/fVUI5DczXkMjwzQrkRwsvzsw5UY7gcD8jmrUk1zRZrSmqkeeP8AWv8ASLGtRXVnPF9klQxTRtuR1ztbBKnjB/P+tUk1SRtLEgY20zBFBeFiUc4yCuATzxkevtSSMNRja1juZLVLeYW7rtw0QRQeDzn0ySOM1oDy47lAsRkJOxZIgPlB5yc9qFZJX3NHaMeWS1GLGxmjKfakuYmcCV0yXU9enGOB1Gfxq1C11LbRJOHZljAcqmADgcFSQetVlsp0W4eGNp5TICHWc4R84J2noAOcc9TWpcSlQ0aH5gOc/T6VLeuhjzXsl/X9XMCa3hjaK2nBETAAnO0xAY27O/UfX86luhcfbneGYy2N1IjHYMkAr9/eTyOB06ehrTi0yO9njlUlAmGKIo/WtG7t1iMwlmAhVB9xc59sYodRXsKVZKVnucu+orb2AJuHjjkOA57cn7uc5PU9MVTaKJ5LhbaXbbsPMMkJBdn642r3weuKuXM9pLBHII3aJwGjDIMZ6hsHkGh5HaRZYoLZ5U6SFVBHbtWqjbVHRF7tIp22h6elhcxSIiCRy4cptYZA4Ax19/p1q5pgstMvm+0hniYq0Z3ldmeuB6j0HH0qcXsxcGeOBmxgfOMfzqG8Fq0UkiwIjqCVffkA4/MfhS956S6hbm0lfXsy7Z3VpZrK8DG7dEZ1lxmNmLEKucE57HHT2FUZIIGjj3yTlpNsiSDhlJbOSc4AxwQQMY6CprfTzH5b2UwSNypkYAE4GcDkH1+tZd9ok8ct3JBLcxTKN29Y8CU44xtIzwD15Gew6qMY33MEkpOzuUtSs0SxUH7SYreTzVWyK7WUNyWweAAcEc9OnNaGlPc2mjJNppiSF9xEwJLtIT1PABGeM9+PSsy11u+jux/bFnbWkEisjSW6FRIxPJJ5xnGfmx168Vq6Re2kjNDaeYqxOdrbg68ZxkDleBnJ46VtNSUbNf5Gkotq8kOku9RsrOC3vLfzppVaZpdg+bruGNxw3GBngkjpgmtE6iYreeCwgvbaJ1U+VJ8zDPUAqTgDj/IIqK1SONWghitppLNftJwDwmcKVH0OK3JWslDyXA2bVyWABAbAITvzyBisJyXb+vQylZbr+vQrWuu3VxNZQGZb2KeMHYsbiZSTjcWUcDkZPHerR1mWwWK01CymmI+T7RG74U5AwxOSevf0NY6JaRIGt7u7RbsqI2fcuMscgZHy9vzArR1K3jsrWRLxzMryYKOSVVs9T6c9SKzlGF0rGcqVNO1v0ZeCWMspW4hilYN83kqyEA+hwATjt79aryaZYmWdbaea0YH7soBz6YI6GqzTWFrbhYbqRvOO7fFJ5gQkcd+h5PGM4NJqVtEs8J8ma9SUhPkj2NAuAcggj8gc0o3T3a/r7hJSi9G1/X3DJ1ntoI44n+1DjcygMcdM8YNEUe2QGSVnDdG2lTgZ64+vpWsJbJIbiJ4lhjRWdXcEMH+p6ZJ/Wi1iSa1ieIjcx4DDB6+p6Hp2xzxVe001RXtrL3lYykVbCZrtHeHHOVJAHqeK07PVJfNinaaSVVO5cORu47kdRz0PFSXFq88ZSPyVIIHzE9+3XHas2OEJcsZkuIZcbcMoKsvsQaLxnuDcKq97c6CXVIbo5ud6pG4Mbpy49T/TGTxWgbn7THKLP93MgKB3Q+uQfccDpXKqSdwyVUcfKBg1cgZtqh3hQg/Kxb7p+lZSpLoc1TDxWx0CW4a3kjupPN3oVfIwDxg8du9ZFxEsGo2yNKhjjXCbx8ykDqCO+BnGKsR3c7ytbyolygTLOhByPT3PtitKG0huArDG1lMeB3GO4/z1rK7huc9/Z/EZmi2MNnuhVJDuw5eQgq5PVgB0PrgAVdYiFZheMoiPAY4Xdx+XtmrcNn5UQjiQ7Y+Ap5IqOSF23rP5ckWRtQqDtPue9S58zuyHUUpXuVo5rQSQgS7ZGw8e0dR6E1bu5rlIhNaW4nmH3ULhckep9O1VLGGaFSlxIsoByjbcED0p16zSbVhuUguCdwJAJZe4x6H2odrikk5HgsHxS8ZeGPinc+DtT0+LX1Fzss5DIlrO8bkGIlz+7Y4KjkZLZG7Ne8XElwsCSPGGiMWZ4GXDqeuAASCR0xk/jWJ4h0fS9TnvZdR062N3fwxac7yqziaJWLhQByMEsd2QQQpzwKr6Zqt34ZvoNG8RzS3ltM2zS9Vf7057W85H/LcAfK3AkA/vZBVmtTCClSa59mdNpNvb7mu7ZHh+1bHf5SpY4wMg9Djj8KoeIdMUW7yCRpGDFm3Nngnp/wDWrc8/MQIKjIyCBgj0Fc7q88hWeK5hWCIEGKQyDDnPOR2PNXTcnO6OqjKXtOa5wm1XvAlsAFfqAfu8cj8c/pWjLIIJIFwzY2707kLzj8z+lOk08PObiCQxyqM5x1NWbOGK4LZUmLlpGB5Iwf8AH9a9GU09T3Kk4vV7EbR+a/muPnfAck9ueBVOK5a1RQFWcqwCr029iR71omYTENFFtVjgDPQVmXW2GeRIlZm3Dy8DgHHJpR10Yqa5lZouLLM92kjwBJ4lzHKT8jkAgqe+3k8Gs3VL6N8XFhEY5sfvredd2xQAQoUDbg7WwxPtntV/Tr0rZ7lKNIAWiI5MnHQZ61pNb2twii6s2LlPMUKMhiPmAwfUjj3qW1CWqMJqMJar+v6/Eh8JeIBqMGyS2Fk8ajcuQV49D17Y/wAau/8ACQw9poSPUbea47U5Li3mhvR9vghuIyfLMx/dNgKeOvY9PrQiaNIiu1nZbmG45OOv/AqTowb5miXh6a96XU1vGdzbWkGj6XeqpcgXPmKhZVk6LkYw3JHHtzxVPXILW0mvNW865RbtPvorbyGUYHHOARnnpT/iRcNpOo2lwgZ3kgiKxkqTNtPIb3A5BHHX1rGs4r26nllubq3haHJkmmY5UspwRxjOOoxjB4zSpK0IyudFGm3RjNOy1v53fb7jY8Eyy3/hzWbe5leSHTLpZ7eSd8ttxluRjgjJH+/Va7WG28Q2DSGOW4uZljXJc7UwpwFHfK9Rx61oeHxaaZoWtaha36X91eBwQICBu2jgDHTGPpWJ450l7ixOoWqSJfJEPLkRsgKA5YY7cHAI5zihNOUtbJ/5L9S6FpYiS2T07a28/M6FdI+zNM8jzPkyPmMjD5JI3AnrjjIHp2osUsrhjbtGxaBlMiEYbcQGwecHAI4rkPButX+oKGvLaY7o9ySiRlWRg3zcHIyck8Y7+tdEdT1Vo1aK0jd7cuWEyctyQpUgkjAODx37UWltcdejVpy9nN3fqbkK2MGqyeUEt7iXg/MVVjjqQOM4qtqtt9qLmyumBVd7bASuF4I3fj0696njaS6gLmOLzNisqjlkO3nPt19Ky1+2Wx8qCYrcgq8ohgGJFJIOAc+vOPepgtbp6nLFNO6eqLFsbvT7YyqzX96sgZkR9ibfRRnngnqeoFampziS3heSQIZNxeKXIIXnpjjOTWJpGlArDPFdBXvSxXzUOWIQgZXOBz1wOfapzp9tBLBa3MkgeLaoIBwrZ7dBkkk4/SiXLzb6+gpRhzXvqvIyJkv5ZZDp97AYU4AaLkH65oshdWdi41BoZXkfAcLkqe2COfzre1SO80y/tIDJB5AhZpLho0DNlvQc5HHPTkUC0unjeQXNrCJ0xEXVTtbPscHp0rT2umtrf15GscQnG+lv68jnr7zYm85JNvG3GMg/n3p1pp1xPPskkDzkZCqNnH58/hWhZ6Pcz390by+huhGUCqhMaRkEEk4bOcHpWvObtfsUtmI52d/3xDZxH3CMOfTrxTlWtpEqWJ+zGxD4d0ryjLNcyR/K/AgkHPrx2I/GpiIrPUJhe3P7yTaBtmyhUHAIQk7Tk49zUFxA6HcjKLxUwJASmVzluec5x+JpjqFtbf7WVmaWJZFmYhgR/e6YzznH8qxd5O7e5zSUpy5m9ynrOl2K6xanaGklbAATcG+XHOR6H/PNWrXwzdkRAlWMThWNufJDqucA+owTkdOar6Loly7XBmee584qUlDDcYwDgHHTluo5wBXpNtKLbToZtSEcEpChwXBAc4GATjJz+dTWrumkk7meJxUqKUYu7KFvppFjLbWyrFNgbXXgDByOhGRmp59JkupImvpUeKNQ3khBt35zn17YrQtbi3aFJIpFaOQDD9QaSW/tQXVZ42kj4ZQwJU4zzXHzyvoeU6tRy0OWuEu7rX99nEsFxZyjEF0zJHJHhgZFZMg53DqOMevSxrbW8enyTQ2yx3Uy+dGsilCTxndxkf8A1qWLXbjyt9xb7CWITtuIJAOeeCOfxqrf6rMwdpkR8f8ALFO/4GtowldabHeo1HKN1t5/11/4cx7maGC2M8cYDSFU+TkjJ6jA5xnv/WqdsjwWcl3JcSrdeWTmWRUWRlBxu7dMfh70/U7N7qGQyKJCWEkSIuxhgdMk8+tU45p3uYLdbbalyGb9667d4A7dfyrr5bxsj0oJW0+fp2H6brMc1lHLqNuX8lB55YZ+UhtrliejY7498VMYrAxLPYRC3dpBsjOQpfbxuVT7A46ce1Nl0e8sYJrzS7hEmuEXzra5UGNscHnGemelLdXNzbTpd30bx27jypBE5IRsffUdNuDyQMg4680Jq/uspqM5Xp9el/wsXL3WHGm215HaPMqSY/0dlIYtlfmPPGe/r6YplrryRzzQ3ayhC8jSNIqlYgvILHIGCMEHr71Y+2yXFzNBAtrJKkZKhfkeRcfKGz1Gf4h/jUGj2ka20f2kWkDCTbFKoGHfJDHAUgZI6kk5JBxUrltqjkcEt0bFvdNlPJu4mhkXKAuW/HbjOPpkU24hcW6vKuI+u5FBAHfp0pqpbOYlDxRSwsYzLDjtztIXj0460uo65DDpsc13cC3VH2GSOJtrYOCMAk5PXBH4GoV7rlRnqpLlRntf23kvNFNLIi8EAHr+P4VftNVkhl320m/acsHYjP1zyD+FSX2jZsvNsJjKjtwwjBwOeSKx7pHt5VeaENbJjHl9Vb157Va5JrQ2j7KqrLU6eDxETxNBIu7ONmM+1RvrpF4DbInkKjZEjFXL9h6Ae9c492qwPNGkkZxyWxnjtjikdYL2zctJKsboRwSm0Ecn2OPSl7CK1sR9TprVo6+Gdbp/NhbbLGuNvmfK/Az26A98VXg0LRctcRQo0mWO4gloyc52kngcnp+Fc1aQrbRW8SysVCZQM2WI7ZJ7f/WqWbUb+IAW7syswJySS3vnt/n0qfYtO0GQ8LJO1OR00OoQW1nbyzTmeOSXy0dUJzk4APU+oJPpnires2Njrej3NnfQJPa3SbJIZBlSO3oQQQCCMEEZGOtczZ38li0zsGlWQ7ypJ44GcE9P8+5qtc65cSOz28rBHYIqkfdYn+XPb0PWodByehjLBSm9C1pd/f8AhzUrTQPEty9xa3DeXperStnzjjiCc9BMOzcCQf7QIOnqskyxNbX1piF3KAn5wygZDfnjg1iakUurO40m/hj1C0uUYTQzKcMAc5yOQc9COQeRzWUkmqWukzW99ftdRRMiWdzK+ZpoyTlZl6F0wP3g4cEHht1KFJqSM6OGnTqRi9U9mOkvUa4nhYYCE5KjKsvTPt+IqSxmKxyIZB87YAzyVB4FUNKi+0vgRlQrHp1ye9TPYyR3xeBhtAG3IPP+ea7Wkm4s9pxhdxuabMILWe5kH7uNSeBkk4zx+tZkEiTTXMjr8pwvPfI9Pyq5LcERIroFDMQVbrj/APV/OqKnzJHji5iT7xA5Lg//AKqIq1yYppNhriD7LFJENpjGxQnHJP6Vfs5rlERzKhh8sAx7CXJJ7HPT/Oap6jGkyInmDy1YduDj/IpNNuFaZ7Z5GRU4BbKn/OaGrwCUU6a8iXUIvtEZaVmaLG1ULH5W9hyP8c1xUgnikaNdJV1UlQ3POO9dzbwsbp4dsm4fMskmGDj356f4VaWNAoBtUJA6l35pRq+z03NKWIVHS1zj7qNNY8f6rba2trPKyOlqfm3xgIdgVeegx05ySazItI1zW7h7eKA2MsLhgkylkjXau5iSMAfd4xnk8dcdlqdxJ5n9pbHsVnVTNMMGSJgcErkDaPvZ9gat6jrN/PBNGzJHEymJBcnyhI3Tgjk8BjgZJ4xjtCnJW5V0t6CWKnG3LFXSS1ezXlt8g0u28jRtKsvNEsMCj9+ibDLnsAOdgyOvpmotUmuNPW5aKNr+GRVlgyNuxmOCuduNoAHcnJPalhNhqCW0ZVDJCij5S2DhQSQTyRn+X1purWF/5cytclLNyArxZzGB1y2eAfas4qz94wilKd5u13d/ff8Aq1jH8k/ZJJpCkMKyEF2DRxpkkfLnk/MBnpmm+cFhd7WWJnt2ZZjKTHgBcnGexB681a1d2v8Aw5dqot7mFd0f7uYFQCnyMSTwRnpzmsWbQ9R/twf2OrwzRhFX7ThleNUCuR1B/hHIzwa2jLuehTSmnzytv+m51NsltHAu11guJIspEvPyjPcjPT86txPFau9yscjTbRvlX5sn0OPrVGS1aXULe6WFpLtYiHTcMKT1GRyfwrdudPis4EkvInklIAVY8lVHqR7VlJpWv1POqSSdpPcy7qe3k1FBFEkSQJ+62Ljy26kkn6GjV7htT0/7PJtOwhiT8gJBDZIB68VWEiW0zEBDGQdrld3HX3p/22KeJ0yis3ChlJwO9Uo6q3QpQ2aWwi3oW0ht0y9vGAuxss+Pqc0+2nimk2QsVHUL5XTtzTZbWL7KvlcE8ZaE5qKGPyctMoKjoQpH6VdotaFpRa0LkunQSvFMJElUE7li4wMdSCeaLk/a91nICiR/xxuUIU59OcjnH4Vl3ihmQ2txLbuD/CAVP4Gr6oZUjR5CcfxIThqTi1ZticGkm2QS25snS7meSRYg+4qGdpFwSoOBg4Lf/rNBmZLFEjhlcN8heeHc6E85bB6fj+ValpYSGZds5KiJYlXknIzkk55JGPfilmjlhuhHOWljmJO1kwqIF7MAep9ff6VPOr9zPnV+7KVvqj22o4eWNIWTA5O7J7dfTv1roNM1NVsREskjheB5js3T1J6/iTWDNbz22jsYVjVlYiMRjgfNwACeuP8A61NQpcNZw34WO9ESyZVyvXg+gHPbk1M4xmRUp06nQ13vppJhHJJEYT91I8ow6dap+Yr3GGBHm/edV6nsCf602X7I2nvePdReVvKSMxIIYHbg5wc5/wA80WVpDDbmORpJjGQ8cxA7k8ZGPbqMfWhJJBFQitPQW7mkhkRPsdx5eQplB+X5u4B6dvzpYktrX5JpVdQPmdkyWXqMnGauxWsk1y9zs2r5aohd3beATkFTwMccjr+FKLeGYNPEsUkTIVYwrvBIHQnNJzVrE+0jazKth5OpeY0ErwkKyANlVXtux65+nHersWn2FrZQQRpHJeRKu1bdtxXOAWG45x179KyLXzYS4s4y8Xm4ETLsCDvgAdvep4LuaI3U6J5UEeMyKnzvj7/HcfhRKLvo9AmpPSL0H6pa6gLyHyJkWOJcSpIm7Kj0PpVXyHkVbW1klhihYpIVAycjO4ZHIya14yskG+OR2mc5LzDkqR054qiltJbzMLL/AEi4B5ETkBc4ABGSFGBngevvQpaWY4T0s+n9amJqMd7pEK/2SBNIsyfaXZ9iENySq9B+GPXmneF9dt71wl7KlrNJK6pE0wXfuYHBA7gdDjBye5xVuS+urppYHhFuXbYPORt5O0kjkemfXp26VkTeFrS504wAGSWTn7QgG8DcOFOQuOCPxNV0tLc7YOm4clfRvqt/+GNER29rKl1fS28sccjnCN8hU8NnGQTjPP8AhWg8lteSxXF8LiGziBmjeInlsjCj5QWGOTkZGRzjmsZNNu9KgtUjvZGhVvLaJlV0aINwCMgZIIBOOtXLvVobe2YojiK0cmRYWx94sNxYnlccEAZyMUP3rNGdSmpO8Hc3rK+kKZiWNp0GxWMhTPPcDg/X+dSatJb3UVw0d5AkrQ+SHkt0cJJnjPHOCfcda5W58RafaL5twFzJtBCAjcc8yKMcrjuCfTFZVvrKWcMNzaTNdWYuG32+4SSFTjKEnPzdSuOo3dxU+zu77ERy+pJ86jY7a1S3eJAivdlQN7IVBHuCM8E+oqtc2T2TGeC6aZSN5jdQzj8F9PbNY2h+KY9zzQ2d8qiRWdQMrbgY2o7MASSxzjp8w966+C4OqMi2KpDKoZ2eTtz3QjI59x+NDcoO/T+v60Mq0KuHl760/r+tDnQrzmCVyN5O5mXBB9M5+vvVhjlfLywfHEgAwT7DP1rXstQ028jnS+BgmjkKyGM/uzxw/UgA5z60h0B7h5JbKRGjIwkquDkH0/Kq9qk/e0E8Qk7VFy2+4pRERLsCmR3A3HdkEemB096eluzQNM+P3fzswAAU88Z+n+FRy6ff2cTLcxOAQV3jnj8Kge7J04RAmSHsp/jYdj37fpRvrFlW5tYO5JcMk0mEUBFUISG54H/181HfLMbOdooBKo27+o44AHtzzTLi822M626os7LmRnOEjOc4z39T3ohnb7I0fmfMy7mCnrjvgfnVJNFpNW02ILKUQWrsicMSFC/wj3P4GrMLRXFpFcQkMGHyvngg5qnC4ktCtvvdCSTsGOOwBPHp3p929w1pChcpsdizDjIOMc/n+dU1qVJXfzLN+Elf5FCooGAfUDqaypd+ZIx9xmyCew7nrVyORYYiJWJJyFHfH/6qoXsrOEJiJycqSTjH/wCqqgraGlOPQvpZB4dytv2ADd1wO1Y9laIt1cPdbHJccvz8wOe/Tn61taRM/wBlitrxslxiQp7D1p9rp8LyFYxwX3KJGyc9s0udxumT7RxumX1libyYZFUxsmGZCSyg9/pVdrO9ViFWNlBwGIXkevWl1CGGzu41m8lGnXDIxGW7AdMEHn8qma3tgxG5uD/eUVhe2qOZO2sXuZz2cJtjIQ5ZYeMu2Put2zzVDRna9NxBdnzYbW4QQo3IUBDj6/jRRQm+VsqLupt/1sReK4otFiD6VFHavLC4do0GTgrj8fmbnrzWrolxLcaMbmWRmmaEEsDj+96UUUPWkm9zpkk8JCXW/wDmRaAfMDSOFZ5JpEckD5grsFz9BWuSfsxfPzbev5f40UUpbnPX+NmPqM0sWpxmKR4zwTsYjOSAc461evbqdlbMjccfrRRWtlZF8q00OcvfmkgJJ6evpiovCkrs1+GYtsnkVd3O0DJGM9Ogoorpt+7kdK/hs6iznlDSr5jYDAAZ+n+JqHxDcyxLuR8MDjJANFFcsUudHNGK9otDNMaXWjRzTorSMvJAx6dhUWnMyBI1ZtgOME57juaKK3js15nStmvM0dfkeLUbCCN2WKcyLIoONw21upI6xooY7QhXnngHpRRXPP4I+hwzV4R/rqytanffGNwGjWXhSMgcHkD1qDU1Gy+kGVkIMZdSQdoJwMjp1NFFSvi+4S+P7iwsUZtCCgIZBnIzn6+tPlmkil1Ao2NsRZQeQCOBx07UUUlq9Sd3r/WxoWQEYAQbRIgZvc/5NO05ESG5gjREi3ldiKFGDnPT+dFFYTOOo3qYAgTT2kNnviLJMxIdjkhRgnJq14cme60a2kuCHkMJYtgA5PU0UVu9YXe+n6nTU1jd73/zHIN2p+UWbyxAcLuP96rs8Ma3A2rjcvze+M4ooqJPYzbfNbyLV7aQLaKwiXdwc9TzmsK/srZvENtGYlCRwPtC8AZxzx3460UVNKT/ADChJ669y5Z2NtGzQiJWilcF0fLBjg9jmsy8s7aLTtQaO2gVpCd58tfm+9145ooqoNt6+RdCcr79jzm7UWvjaxith5Mcsa71T5Qc5B6dOPSu3sbeBfD92wt7cllwxMSnPOecjrknmiitqy9xP+tz6HHN8lLzS/Mw3uJdO0GzurJvJnuGjEzAD95uRmO4Hg8/l2rasII7iRGkBzHboU2sVA2+djgY44HHQ45ooqajtBtdzHEK1JyW93+aOd0/ULq+tmnu5jJNFeOkbkAFV3IMDH1P511/hF3ubcTzSSGVpEywcjsfSiitqqtB2M8xioxlyq2pq22o3i63DALmUxNEzFSxIyCQK2ta061vNMeS4jJdCSrK7KRj6EetFFcdf3ZRcdP+HPDxPuTi46f8OefeIJ3N1FESpj8+NdpUHjaT/MVowDbI5HU5/mRRRXc/gR6zXuIbpbH+0XX+FG2qOwFO1NirptOMvg/kT/QUUVC+Mzj/ABGZsH7yaHzPmwxxnmpm5cA8jcvB59P8aKK0lubS3L9uoLsSBwrEexBAFWdIuJJ7ZpZWDSKeDgCiisKnws5avw/Mpayi3MltNON0iqzA5wMgEjgcHB5ppnlJJMjZPvRRQ9kXFLlX9dWf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of an intermediate stage of chronic vascular rejection in an interlobular artery. The arterial lumen is narrowed by marked subintimal thickening with loose connective tissue (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10549=[""].join("\n");
var outline_f10_19_10549=null;
var title_f10_19_10550="Management of stage II nonseminomatous germ cell tumors";
var content_f10_19_10550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of stage II nonseminomatous germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/19/10550/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/19/10550/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/19/10550/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/19/10550/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/19/10550/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/19/10550/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/19/10550/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/19/10550/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancers, 95 percent of which are germ cell tumors (GCTs), are one of the most curable solid neoplasms, with a five-year survival rate of over 95 percent. Testicular cancer accounts for approximately 200 to 800 cases per 100,000 men worldwide with fewer than 350 cancer deaths per 100,000 men each year.",
"   </p>",
"   <p>",
"    Testicular GCTs are more sensitive to systemic chemotherapy than most adult solid tumors. Therefore, chemotherapy is routinely administered for men with advanced seminoma or nonseminomatous germ cell tumors (NSGCTs) (ie, stage III disease, (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 2",
"    </a>",
"    )) and for those with persistently elevated serum tumor markers following orchiectomy (stage Is). The success of chemotherapy in advanced disease has led to its use in men with stage I and II disease to improve outcome and decrease treatment-related morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of stage II NSGCT following orchiectomy will be reviewed here. An overview of the management of testicular cancer and the management of other stages of testicular cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"     \"Management of stage I nonseminomatous germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84900588\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage II disease can be defined based on imaging alone (",
"    <strong>",
"     clinical stage II",
"    </strong>",
"    ) or following a retroperitoneal lymph node dissection (RPLND) based on the confirmation of pathologically involved lymph nodes (",
"    <strong>",
"     pathologic stage II",
"    </strong>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The treatment approach to clinical stage II and pathologic stage II nonseminomatous germ cell tumors (NSGCTs) are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110956445\">",
"    <span class=\"h1\">",
"     CLINICAL STAGE II NSGCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with clinical stage II disease who normalize their serum tumor markers post-orchiectomy, adjuvant treatment is associated with a high likelihood of cure. The options for adjuvant therapy include primary chemotherapy or retroperitoneal lymph node dissection (RPLND).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110956505\">",
"    <span class=\"h2\">",
"     Clinical stage IIA disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who present with one or more regional nodes measuring &le;2 cm in greatest dimension can present a therapeutic challenge because computed tomography (CT) is not reliable enough to evaluate the presence of nodal disease. The positive predictive value of CT scan ranges from 64 to 88 percent and negative predictive value is approximately 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. However, these men have a high likelihood of having pathologic stage I disease at RPLND. &nbsp;",
"   </p>",
"   <p>",
"    Therefore, we prefer RPLND for definitive staging rather than primary chemotherapy. RPLND cures 80 to 90 percent of men with stage IIA nodal disease. In addition, it spares a substantial number of patients (who would be pathologically downstaged to stage I NSGCT) from unnecessary chemotherapy. This is consistent with guidelines from the European Germ Cell Cancer Consensus Group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link&amp;anchor=H12#H12\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\", section on 'Stage I and II GCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84900603\">",
"    <span class=\"h2\">",
"     Clinical stage IIB/C disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike men with clinical stage IIA NSGCT, the cure rate following RPLND for men with a nodal mass &gt;2 cm (clinical stage",
"    <span class=\"nowrap\">",
"     IIB/C",
"    </span>",
"    disease) is 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Because of this and the likelihood that nearly all these men will have pathologically confirmed nodal disease if they undergo RPLND (ie, pathologic stage",
"    <span class=\"nowrap\">",
"     IIB/C",
"    </span>",
"    disease), we prefer to manage these patients with primary chemotherapy rather than RPLND. This allows earlier treatment for men who may have micrometastatic disease and spares men from the morbidity of RPLND if they have a complete response to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ]. Our preferred regimen is two cycles of chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (BEP or EP). Men with evidence of residual masses on postchemotherapy imaging should proceed with an RPLND.",
"   </p>",
"   <p>",
"    There are no randomized trials that compare primary systemic chemotherapy with RPLND for patients in this clinical setting. In addition, patients were not identified for treatment using established prognostic factors (eg, T stage, the presence of vascular invasion, the presence of teratomatous elements in the primary tumor, or the volume of embryonal carcinoma) in studies reporting the role of primary systemic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ]. Despite these caveats, the available data suggest that chemotherapy results in similar survival outcomes compared to RPLND for men with stage IIA disease and that it may be superior for men with stage IIB-IIC disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/3,4,9-11\">",
"     3,4,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary chemotherapy for clinical stage II NSGCTs generally consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP) for three cycles (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 3",
"    </a>",
"    ) or EP for four cycles. This is based on the results of treatment using this regimen in advanced GCTs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110956512\">",
"    <span class=\"h3\">",
"     RPLND after chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who have residual masses following chemotherapy, we suggest RPLND rather than observation. The role of RPLND after chemotherapy in men with clinical stage II NSGCTs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgical management of advanced testicular germ cell tumors\", section on 'Nonseminomatous GCTs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGIC STAGE II NSGCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic stage II disease (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 2",
"    </a>",
"    ) refers to histologically confirmed retroperitoneal lymph node involvement. Typically it presents an upstaging of men felt to have clinical stage I disease who are diagnosed with nodal involvement following a retroperitoneal lymph node dissection (RPLND). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link&amp;anchor=H8532060#H8532060\">",
"     \"Management of stage I nonseminomatous germ cell tumors\", section on 'Retroperitoneal lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with pathologic stage II NSGCT can be managed with either adjuvant chemotherapy or careful surveillance. If recurrence is detected during surveillance, systemic chemotherapy should be administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Decisions regarding treatment are largely based upon the volume of disease. Extranodal extension as an isolated pathologic finding does not appear to be an additional risk factor beyond the extent of disease in the retroperitoneal lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathologic stage IIA disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 85 to 90 percent of men with pathologic stage IIA disease are cured with RPLND, provided their tumor markers have normalized. We suggest active surveillance for these men rather than adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link&amp;anchor=H900676917#H900676917\">",
"     \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\", section on 'Active surveillance protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, patients who are unlikely to comply with a surveillance schedule following RPLND should receive two cycles of adjuvant chemotherapy. In addition, it is reasonable to administer chemotherapy to men who wish to be aggressive with treatment in order to reduce the risk of relapse from 10 to 15 percent down to 1 percent, provided they are aware that there is no improvement in overall survival associated with adjuvant chemotherapy. For some men, the peace of mind this provides is worth undergoing six weeks of chemotherapy.",
"   </p>",
"   <p>",
"    The equivalence between surveillance and adjuvant chemotherapy was shown in a trial involving 195 men with pathologic stage II disease who were randomly assigned to surveillance or adjuvant chemotherapy (two cycles of a platinum-containing regimen) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who relapsed while on surveillance were treated with three or four cycles of chemotherapy. The main results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The recurrence rate was 6 and 49 percent following adjuvant chemotherapy or surveillance, respectively.",
"     </li>",
"     <li>",
"      The risk of relapse during surveillance varied according to the volume of disease identified in the lymph nodes. For men with nodes &gt;2 cm, nodes &le;2 cm, and microscopically involved nodes, it was 60, 53, and 40 percent, respectively. However, this difference was not statistically significant.",
"     </li>",
"     <li>",
"      However, there were no statistically significant differences in the risk of relapse in men with microscopically positive nodes, nodes &le;2 cm, and nodes &gt;2 cm (40 versus 53 and 60 percent, respectively).",
"     </li>",
"     <li>",
"      At a median follow-up of four years, there was no statistically significant difference in the survival rates between the two groups with three deaths from testicular cancer in the surveillance arm and one in the chemotherapy arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathologic stage IIB/C disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike men with pathologic stage IIA disease, the relapse-free survival rates are lower for men with nodal disease &gt;2 cm (stage IIB or IIC disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/9,13-20\">",
"     9,13-20",
"    </a>",
"    ]. Therefore, we suggest adjuvant chemotherapy rather than observation for these men.",
"   </p>",
"   <p>",
"    Two cycles of BEP (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 3",
"    </a>",
"    ) or EP represent standard adjuvant chemotherapy in the post-RPLND setting for men who undergo chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10550/abstract/6,15,21-24\">",
"     6,15,21-24",
"    </a>",
"    ]. No comparative trials have been performed comparing the two regimens but each has been associated with a relapse rate of about 1 percent. As with the role of chemotherapy for men with clinical stage IIA disease, the benefit of chemotherapy is extrapolated from their administration for men with advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H126221925\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tumor burden (denoted by stage) is used to make treatment recommendations, the histology of the primary tumor should also be taken in to consideration. As an example, men with lymphovascular invasion and a high proportion of embryonal carcinoma in their primary tumor are at higher risk of relapse following RPLND compared to those without these features. For patients who are borderline between stage IIA and IIB, such features would lead us to favor chemotherapy as the initial treatment. In contrast, men with pure teratomas are less likely to benefit from chemotherapy and we tend to prefer RPLND over chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular germ cell tumors (GCTs) are more sensitive to systemic chemotherapy than most adult solid tumors. The success of chemotherapy in advanced disease has led to its use in men with stage I and II disease to improve outcome and decrease treatment-related morbidity.",
"     </li>",
"     <li>",
"      For men with clinical stage II nonseminomatous germ cell tumors (NSGCTs) and normal serum tumor markers, the size of lymph nodes is used to determine whether to proceed with a retroperitoneal lymph node dissection (RPLND) or to administer primary chemotherapy. Size criteria is used to determine",
"      <strong>",
"       non-bulky",
"      </strong>",
"      (stage IIA) or",
"      <strong>",
"       bulky",
"      </strong>",
"      (stage IIB or IIC) disease using the greatest dimension of lymph nodes (&le;2 cm, 2 to 5 cm, or &gt;5 cm, respectively). (See",
"      <a class=\"local\" href=\"#H84900588\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H110956445\">",
"       'Clinical stage II NSGCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men with clinical stage IIA NSGCT, we suggest RPLND rather than primary chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These men have a high likelihood of having pathologic stage I disease if tumor involvement is identified at surgery. Patients with evidence of metastatic testicular cancer confirmed at surgery are managed according to their pathologic stage. (See",
"      <a class=\"local\" href=\"#H110956505\">",
"       'Clinical stage IIA disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with clinical stage IIB and IIC NSGCT, we suggest primary chemotherapy rather than RPLND (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use three cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (BEP) (",
"      <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"       table 3",
"      </a>",
"      ). However, etoposide and cisplatin (EP) for four cycles is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H84900603\">",
"       'Clinical stage IIB/C disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men who have residual masses following chemotherapy should undergo a postchemotherapy RPLND. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H7#H7\">",
"       \"Surgical management of advanced testicular germ cell tumors\", section on 'Nonseminomatous GCTs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with pathologic stage II NSGCT, pathologic information is used to determine whether or not adjuvant chemotherapy should be administered following RPLND. (See",
"      <a class=\"local\" href=\"#H84900588\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men with pathologic stage IIA NSGCT, we suggest surveillance rather than adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, patient preference should be taken into account in the formulation of the treatment plan. Adjuvant chemotherapy is reasonable for patients who prefer an aggressive approach to treatment in order to minimize the risk of relapse and for those who may not be able to comply with a surveillance schedule. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathologic stage IIA disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pathologic stage IIB or IIC disease, we suggest two cycles of adjuvant chemotherapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      . However, etoposide and cisplatin is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathologic stage IIB/C disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/1\">",
"      Stomper PC, Fung CY, Socinski MA, et al. Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. AJR Am J Roentgenol 1987; 149:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/2\">",
"      Donohue JP, Thornhill JA, Foster RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995; 153:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/3\">",
"      Weissbach L, Bussar-Maatz R, Flechtner H, et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000; 37:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/4\">",
"      Stephenson AJ, Bosl GJ, Motzer RJ, et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 2007; 25:5597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/5\">",
"      Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/6\">",
"      Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987; 317:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/7\">",
"      Logothetis CJ, Swanson DA, Dexeus F, et al. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol 1987; 5:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/8\">",
"      Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/9\">",
"      Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005; 23:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/10\">",
"      Donohue JP, Thornhill JA, Foster RS, et al. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 1995; 31A:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/11\">",
"      Chung PW, Bedard P. Stage II seminomas and nonseminomas. Hematol Oncol Clin North Am 2011; 25:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/12\">",
"      Beck SD, Cheng L, Bihrle R, et al. Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy? J Urol 2007; 177:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/13\">",
"      Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000; 163:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/14\">",
"      Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001; 19:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/15\">",
"      Hartlapp JH, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 1987; 10:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/16\">",
"      Pizzocaro G, Piva L, Salvioni R, et al. Adjuvant chemotherapy in resected stage-II nonseminomatous germ cell tumors of testis. In which cases is it necessary? Eur Urol 1984; 10:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/17\">",
"      Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991; 9:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/18\">",
"      Tait D, Peckham MJ, Hendry WF, Goldstraw P. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 1984; 50:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/19\">",
"      Donohue JP, Thornhill JA, Foster RS, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993; 149:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/20\">",
"      Beck SD, Foster RS, Bihrle R, et al. Impact of the number of positive lymph nodes on disease-free survival in patients with pathological stage B1 nonseminomatous germ cell tumor. J Urol 2005; 174:143.",
"     </a>",
"    </li>",
"    <li>",
"     Motzer RJ, et al. National Comprehensive Cancer Network Practice Guidelines in Oncology: Testicular Cancer, National Comprehensive Cancer Network, Rockledge, PA 2001. Vol Version 1.2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/22\">",
"      Behnia M, Foster R, Einhorn LH, et al. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer 2000; 36:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/23\">",
"      Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004; 22:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10550/abstract/24\">",
"      Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 1995; 13:2700.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2976 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-E320E62127-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10550=[""].join("\n");
var outline_f10_19_10550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84900588\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110956445\">",
"      CLINICAL STAGE II NSGCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110956505\">",
"      Clinical stage IIA disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84900603\">",
"      Clinical stage IIB/C disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110956512\">",
"      - RPLND after chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGIC STAGE II NSGCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathologic stage IIA disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathologic stage IIB/C disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H126221925\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2976|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 1\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/34/21037\" title=\"table 2\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 3\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=related_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=related_link\">",
"      Management of stage I nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_19_10551="Zuclopenthixol: Drug information";
var content_f10_19_10551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zuclopenthixol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/1/31765?source=see_link\">",
"    see \"Zuclopenthixol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F236396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clopixol-Acuphase&reg;;",
"     </li>",
"     <li>",
"      Clopixol&reg;;",
"     </li>",
"     <li>",
"      Clopixol&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F236431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F236400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Management of schizophrenia/psychoses:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute psychosis: Initial: 10-50 mg/day in 2-3 divided doses; may titrate dose upward by 10-20 mg every 2-3 days; usual dosage range: 20-60 mg/day; maximum dose: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance therapy: Maintain lowest effective dose; usual maintenance dose: 20-40 mg/day; may be given as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute psychosis:",
"     </b>",
"     Zuclopenthixol acetate: I.M.: Usual dose: 50-150 mg; may be repeated in 2-3 days (some patients may require an additional dose 1-2 days after the initial dose and then repeat every 2-3 days as necessary); no more than 400 mg or 4 injections should be given in the course of treatment; maximum treatment period: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transfer of patients from I.M. acetate to oral tablets:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Allow 2-3 days after final injection before initiating oral therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50 mg of acetate injection every 2-3 days = 20 mg daily of oral tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     100 mg of acetate injection every 2-3 days = 40 mg daily of oral tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     150 mg of acetate injection every 2-3 days = 60 mg daily of oral tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Long-term management of psychosis:",
"     </b>",
"     Zuclopenthixol decanoate: I.M.: Maintenance therapy: Usual maintenance dose: 150-300 mg every 2-4 weeks; dose increase or reduction and/or more frequent administration may be required in some patients. Maintain lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transfer of patients from oral tablets to I.M. decanoate:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;20 mg daily of oral tablets = 100 mg of decanoate injection every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25-40 mg daily of oral tablets = 200 mg of decanoate injection every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50-75 mg daily of oral tablets = 300 mg of decanoate injection every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">",
"     &gt;75 mg/day of oral tablets = 400 mg of decanoate injection every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transfer of patients from I.M. acetate to I.M. decanoate:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     When initiating maintenance therapy with decanoate, may administer initial dose concomitantly with final acetate injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50 mg of acetate injection every 2-3 days = 100 mg of decanoate injection every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     100 mg of acetate injection every 2-3 days = 200 mg of decanoate injection every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     150 mg of acetate injection every 2-3 days = 300 mg of decanoate injection every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13253921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling; however, renal impairment is not likely to influence systemic exposure as the drug undergoes extensive hepatic metabolism and is primarily excreted in the feces.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13253920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling. Zuclopenthixol undergoes extensive hepatic metabolism. Use caution.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clopixol Acuphase&reg;: 50 mg/mL [zuclopenthixol 42.5 mg/mL] (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, as decanoate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clopixol&reg; Depot: 200 mg/mL [zuclopenthixol 144.4 mg/mL] (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dihydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clopixol&reg;: 10 mg, 25 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10286830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Acetate or decanoate: Administer by deep injection into the gluteal region. Injection volumes exceeding 2 mL should be distributed between 2 injection sites. When administration of the acetate",
"     <b>",
"      and",
"     </b>",
"     decanoate formulations is necessary (eg, exacerbation of chronic psychosis), may mix the acetate and decanoate formulations in the same syringe and administer as a single injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Tablets should be administered in 2 or 3 divided doses with initial dosing; may switch to once-daily administration at bedtime during maintenance treatment. May be administered without regards to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F236379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of schizophrenia; acetate injection is intended for short-term acute treatment; decanoate injection is for long-term management; hydrochloride tablets may be used in either the initial or maintenance phase",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F236429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Incidence reported with oral formulation unless otherwise noted. Reported incidence with injection includes decanoate and/or acetate formulations.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence/drowsiness (32%; injection 16% to 20%), anxiety/nervousness (17%; injection 4% to 9%), insomnia (16%; injection 5% to 10%), akathisia (14%; injection 13% to 16%), extrapyramidal effects (13%; injection 1% to 12%), dizziness (11%; injection 7% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (15%; injection 13% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hypertonia (19%; injection 5% to 26%), tremor (19%; injection 8% to 21%), weakness (15%; injection 8% to 14%), hypokinesia (7%; injection 10% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (4%; injection 3% to 10%), orthostatic hypotension (3%; injection &le;1%), hypotension (2%), palpitation (1%; injection &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (10%; injection 1%), depression (8%; injection 3% to 7%), concentration impaired (8%; injection 3% to 4%), dystonia (5%; injection 7% to 14%), headache (5%; injection 1% to 5%), vertigo (5%; injection 1% to 2%), tardive dyskinesia (3%; injection &le;1%), apathy (3%; injection 1% to 2%), confusion (3%; injection &le;1%), amnesia (3%; injection 2%), hallucination (&le;3%), abnormal dreams (2%; injection 2%), malaise (2%), pain (2%), paresthesia (1%; injection 2% to 3%), pallor (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Seborrhea (2%; injection &le;1%), pruritus (injection &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (3%; injection &le;1%), menstrual disorder (2%; injection &le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (8%; injection 1% to 6%), salivation increased (8%; injection 6% to 10%), anorexia (4%; injection &le;2%), weight gain (4%; injection &le;2%), vomiting (3%; injection 1% to 2%), weight loss (3%; injection &le;2%), nausea (2%; injection 1%), appetite increased (1%; injection &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Micturition disorder (3%; injection 1% to 3%), ejaculation impaired (&le;1%; injection &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait (2%; injection &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal accommodation (6%; injection 4% to 11%), abnormal vision (4%; injection &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased (3%; injection 1% to 6%), thirst (1%; injection &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      All formulations:",
"     </b>",
"     &le;1% (Limited to important or life-threatening): Agranulocytosis, allergic reaction, anaphylactic reaction,  apnea, arthritis, ataxia, chest pain, cholestatic hepatitis, corneal deposits, dermatitis, dysphagia, dyspnea, dyskinesia, galactorrhea, gastric ulcer, glossitis, gynecomastia, hypotension, hyperbilirubinemia, hyperglycemia, hyperlipidemia, hyperprolactinemia, hyperreflexia, hypothermia, jaundice, lens opacity, leukopenia, liver function abnormal, muscle rigidity, myalgia, oculogyric crisis, neuroleptic malignant syndrome (NMS), neutropenia, orthostatic hypotension, parkinsonism, paroniria, peripheral edema, photosensitivity, purpura, QT interval prolonged, rash (including erythematous and psoriasiform rash), respiratory depression, seizure, syncope, thrombocytopenia, tinnitus, torsade de pointes, torticollis, trismus, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F236382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zuclopenthixol, thioxanthenes, or any component of the formulation; acute intoxication (ethanol, barbiturate, or opioid); CNS depression; coma; suspected or established subcortical brain damage; circulatory collapse",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F236366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Avoid use in patients with underlying QT prolongation, in those taking medicines that prolong the QT interval, or cause polymorphic ventricular tachycardia; monitor ECG closely for dose-related QT effects. Adverse effects of decanoate may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, zuclopenthixol has a low potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, prolonged therapy, use of conventional antipsychotics, males, and younger patients. Risk of tardive dyskinesia may be increased in elderly patients; antipsychotics may also mask signs/symptoms of tardive dyskinesia. Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS):",
"     <b>",
"      [Canadian Boxed Warning]: NMS has been associated with use of antipsychotic agents, including zuclopenthixol;",
"     </b>",
"     monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia). Discontinue treatment immediately with onset of NMS; recurrence has been reported in patients rechallenged with antipsychotic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular: Similar drugs have been associated with pigmentary retinopathy, corneal deposits, and photosensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Venous thromboembolism (VTE): VTE has been reported with antipsychotics; evaluate VTE risk prior to and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: Use caution when withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Abrupt cessation may cause (rarely) acute withdrawal symptoms (eg, nausea, vomiting, or insomnia). Symptoms usually observed within 4 days of withdrawal and subside within 1-2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (including fatalities) has been reported in elderly patients with dementia-related psychosis. Zuclopenthixol is not approved for use in elderly patients with dementia or dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use is not recommended in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; undergoes hepatic metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolactin-dependent tumors: Use with caution in patients with breast cancer or other prolactin-dependent tumors; elevates prolactin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage (subcortical-contraindicated), alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in the elderly; increased risk of tardive dyskinesia, particularly in elderly women.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F236425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F236370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Zuclopenthixol. Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F236394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization). Avoid kava kava, gotu kola, valerian, St John's wort (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13253416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F236402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F236374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; hepatic function, lipid profile, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F236385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ciatyl-Z (DE);",
"     </li>",
"     <li>",
"      Ciatyl-Z Acuphase (DE);",
"     </li>",
"     <li>",
"      Ciatyl-Z Depot (DE);",
"     </li>",
"     <li>",
"      Cisordinol (AT, CN, CZ, DK, EE, FI, HN, HU, NO, PE, PT, SE);",
"     </li>",
"     <li>",
"      Cisordinol Acutard (CN, EE, FI, PE, PT, SE);",
"     </li>",
"     <li>",
"      Cisordinol Depot (AT, CN, DK, EE, FI, HN, HU, NO, PE, PT, SE);",
"     </li>",
"     <li>",
"      Cisordinol-Acutard (NO);",
"     </li>",
"     <li>",
"      Cisordinol-Acutard[inj.] (HU);",
"     </li>",
"     <li>",
"      Clopixol (AR, AU, BE, BG, BR, CH, CL, ES, FR, GB, GR, HK, IE, IL, IT, LU, MX, MY, NL, PK, PL, RU, SG, TH, TR, TW, ZA);",
"     </li>",
"     <li>",
"      Clopixol Acuphase (BR, HK, IL, IN, IT, MX, MY, PK, ZA);",
"     </li>",
"     <li>",
"      Clopixol Acutard (CH);",
"     </li>",
"     <li>",
"      Clopixol Depot (BR, CH, CL, HK, IL, IN, IT, LU, MX, MY, NL, PK, SG, TH, TW, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F236365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zuclopenthixol is a thioxanthene antipsychotic with a piperazine side chain; related to fluphenazine, the cis(z)-clopenthixol is the active isomer of this neuroleptic; blocks postsynaptic dopaminergic (D",
"     <sub>",
"      1",
"     </sub>",
"     and D",
"     <sub>",
"      2",
"     </sub>",
"     ) brain receptors. Also has high affinity for 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     and alpha-1 adrenergic receptors, and a  weaker affinity for histamine",
"     <sub>",
"      1",
"     </sub>",
"     -receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F236381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Acetate injection: Sedation within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Acetate injection: 2-3 days; Decanoate injection: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 20 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via sulfoxidation, and N-dealkylation; (",
"     <i>",
"      in vitro",
"     </i>",
"     data suggests that metabolism may occur via CYP2D6 and CYP3A4 [Davies, 2010]); also undergoes glucuronidation. Metabolites are inactive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Oral: ~20 hours; Depot: 19 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Tablet: ~4 hours; Acetate injection: 24-48 hours; Decanoate injection: 3-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Mostly feces; urine (~10%; minimal amount as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Psychiatric Association, \"Clinical Practice Guidelines. Treatment of Schizophrenia,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2005, 50(13 Suppl 1):7-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/19/10551/abstract-text/16529334/pubmed\" id=\"16529334\" target=\"_blank\">",
"        16529334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies SJ, Westin AA, Castberg I, et al, &ldquo;Characterisation of Zuclopenthixol Metabolism by",
"      <i>",
"       in vitro",
"      </i>",
"      and Therapeutic Drug Monitoring Studies,&rdquo;",
"      <i>",
"       Acta Psychiatr Scand",
"      </i>",
"      , 2010, 122(6):444-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/19/10551/abstract-text/20946203/pubmed\" id=\"20946203\" target=\"_blank\">",
"        20946203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirshberg B, Gural A, and Caraco Y, &ldquo;Zuclopenthixol-Associated Neutropenia and Thrombocytopenia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(6):740-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/19/10551/abstract-text/10860136/pubmed\" id=\"10860136\" target=\"_blank\">",
"        10860136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10127 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10551=[""].join("\n");
var outline_f10_19_10551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236396\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236431\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236400\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062224\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13253921\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13253920\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076368\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234390\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10286830\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236379\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236429\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236382\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236366\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236425\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236370\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236394\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13253416\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236402\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236374\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236385\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236365\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236381\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10127\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10127|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/1/31765?source=related_link\">",
"      Zuclopenthixol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_19_10552="WHO weight for age boys 0 to 24 months";
var content_f10_19_10552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50006%7EPEDS%2F71721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50006%7EPEDS%2F71721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, boys 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 532px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 688px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10552=[""].join("\n");
var outline_f10_19_10552=null;
var title_f10_19_10553="Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis";
var content_f10_19_10553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/19/10553/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/19/10553/contributors\">",
"     Kenneth R Silk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/19/10553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/19/10553/contributors\">",
"     Andrew Skodol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/19/10553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/19/10553/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/19/10553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Personality consists of enduring patterns of perceiving, relating to, and thinking about the environment and oneself that are exhibited in numerous social and personal contexts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ]. A personality disorder arises when personality traits are so inflexible and maladaptive across a wide range of situations that they cause significant impairment of social, occupational, and role functioning or subjective distress. In addition, the thinking, displays of emotion, impulsivity, and interpersonal behavior of the individual must deviate markedly from the expectations of the individual's culture in order to qualify as a personality disorder. There are 10 personality disorders included in the American Psychiatric Association Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69002 \" href=\"UTD.htm?21/31/22012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Borderline personality disorder (BPD) is characterized by instability of interpersonal relationships, self-image, and emotions and by impulsivity. The name of the disorder was originally based upon a concept that this syndrome constituted the boundary or borderline between neurosis (a pattern of maladaptive traits and coping mechanisms) and psychosis (a condition of grossly impaired reality testing) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with BPD receive extensive clinical attention and the disorder is more widely studied than any other personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Despite these efforts, patients with BPD continue to suffer considerable morbidity and mortality.",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and differential diagnosis of BPD will be reviewed here. The treatment and prognosis of BPD and other personality disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link\">",
"     \"Borderline personality disorder: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link\">",
"     \"Personality disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPD is common in both the general population and in clinical settings. Large, nationally representative, nonclinical surveys of the US general population estimate that the point prevalence of BPD is 1.4 percent and the lifetime prevalence is 5.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Studies in clinical settings found BPD was present in 6.4 percent of urban primary care patients, 9.3 percent of psychiatric outpatients, and about 20 percent of psychiatric inpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ratio of females to males with the disorder is greater in clinical populations than it is in the general population. The ratio is 3:1 in clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ]. However, multiple epidemiologic surveys of the US general population have found the lifetime prevalence of BPD does not differ significantly between men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This discrepancy suggests that women with BPD are more likely to seek treatment than men.",
"   </p>",
"   <p>",
"    The relationship between BPD and ethnicity differs between clinical and epidemiological studies. A study of patients presenting to clinical facilities found significantly higher rates of BPD in Hispanics compared with Caucasians and African Americans (64 versus 39 versus 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, a US epidemiologic study found the prevalence of BPD was not significantly related to race and ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The point prevalence of BPD is not significantly related to family income or marital status [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Economic costs and health care utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The costs of BPD are substantial. A 2008 study of the total economic burden of personality disorders examined the direct costs of medical care and the indirect costs of productivity losses due to absenteeism and reduced efficiency at work [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with BPD incurred significantly more total costs per year compared to patients without a personality disorder (approximately 3,500 euros or 4,655 dollars). In addition, direct costs and indirect costs per year were each significantly more for BPD, compared to nearly every other personality disorder.",
"   </p>",
"   <p>",
"    Patients with BPD often use mental health treatment resources. A longitudinal study found that patients with BPD were significantly more likely than patients with major depressive disorder to receive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Individual psychotherapy (OR 2.6, 95% CI 1.6-4.3)",
"     </li>",
"     <li>",
"      Psychotropic medication (OR 2.7, 1.6-4.4)",
"     </li>",
"     <li>",
"      Treatment in a psychiatric emergency department (OR 2.3, 1.2-4.7)",
"     </li>",
"     <li>",
"      Treatment as a psychiatric inpatient (OR 4.0, 2.1-7.8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of BPD is largely unknown. Most hypotheses state that BPD is due to a combination of multiple, interacting factors, including biological (genetic) vulnerability, certain life experiences (often traumatic), and reinforced interpersonal behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/12\">",
"     12",
"    </a>",
"    ]. It is not known whether there are different subtypes of the disorder with different etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychosocial causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of childhood trauma is common in patients with BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the relationship between abuse and BPD is not clear. Childhood trauma is not always present in patients with BPD, and many individuals who suffer abuse do not develop BPD.",
"   </p>",
"   <p>",
"    The trauma that is often present in the history of patients with BPD can take many forms, including sexual abuse, physical abuse, verbal abuse, neglect, and early parental separation or loss. A systematic review found high rates of childhood sexual (16 to 71 percent) and physical (10 to 73 percent) abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/13\">",
"     13",
"    </a>",
"    ]. In one large clinical sample, 61 percent of patients with BPD reported a history of childhood sexual abuse and 59 percent reported physical abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, a history of childhood sexual abuse by a male noncaretaker was significantly associated with an adult diagnosis of BPD. A prospective, community based, longitudinal study of children found that childhood abuse or neglect was eventually and significantly associated with BPD in young adulthood, after controlling for parental education and parental psychopathology (OR 7.7, 95% CI 1.8-33.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies, however, indicate that childhood sexual abuse is not a major risk factor or causal antecedent of BPD. Meta-analyses have found only small effect sizes for the association between childhood sexual abuse and BPD, as well as the association between childhood sexual abuse and self-injurious behavior (a common manifestation of BPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Another meta-analysis found that college students with a history of childhood sexual abuse were only slightly less well-adjusted than control students [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, poorer adjustment could not be attributed to childhood sexual abuse because family environment was consistently confounded with childhood sexual abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic basis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is modest evidence for the genetic transmission and heritability of BPD. Two studies found the concordance rate for BPD was higher in monozygotic twins compared with dizygotic twins (35 and 36 percent versus 7 and 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A third twin study found the proportion of variance in BPD in the general community explained by environmental influences was greater than that explained by genetic influences (58 versus 42 percent of the variance) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach to studying the disorder's genetic basis has tried to identify the heritability of endophenotypes, such as certain psychopathologic behaviors. A review supported the idea that a constitutional predisposition to emotion dysregulation, combined with a non-validating (non-supporting) environment, leads to the development of BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biological correlates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preclinical research suggests that perhaps altered neuropeptide function underlies the interpersonal problems of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, numerous neurotransmitter and neuroimaging studies have compared patients with BPD to healthy controls, and found abnormalities such as serotonin dysfunction and bilateral reductions in the hippocampus, amygdala, and other regions of the medial temporal lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It is difficult to interpret such results because the studies enrolled and investigated adult patients who already met criteria for BPD. Thus, it is not clear whether the observed neurobiological correlates represent etiologic causes or sequelae of the disorder. Making this distinction requires a longitudinal study that enrolls premorbid children or adolescents. The specificity of the neurotransmitter and neuroimaging findings to BPD is also unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core features of BPD are instability of interpersonal relationships, self-image, and affects, and marked impulsivity.",
"   </p>",
"   <p>",
"    Factor analysis of the DSM-III-R diagnostic criteria for BPD revealed three homogenous components or dimensions of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired relatedness - unstable relationships with others, identity disturbance, and chronic emptiness",
"     </li>",
"     <li>",
"      Affective dysregulation - affective lability, excessive anger, and efforts to avoid abandonment",
"     </li>",
"     <li>",
"      Behavior dysregulation - impulsivity, suicidality, and self-injurious behavior",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interpersonal difficulties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BPD usually have stormy relationships, especially with people to whom patients are close [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/27\">",
"     27",
"    </a>",
"    ]. At one moment a friend or romantic partner may be viewed not only as a trusted confidant but as an ideal, almost perfect person, and then this same individual can suddenly be seen as cruel, betraying, very limited, and damaged. When the idealized person is present and supportive, the patient feels strong and solid. However, if the support person leaves (or is unable to meet the patient's needs) for a limited period of time or if the patient thinks that the support person is about to leave, the patient can immediately become angry, demeaning, depressed, hopeless, and suicidal.",
"   </p>",
"   <p>",
"    Patients tend to view others as all good or all bad, a phenomenon that has been labeled \"splitting\" [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/28\">",
"     28",
"    </a>",
"    ]. Rigidly classifying other people as good or bad can lead the patient to shift between extreme points of view and to selectively attend to information in a way that confirms his or her current opinion. This tendency to \"split\" can impact treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link&amp;anchor=H2#H2\">",
"     \"Borderline personality disorder: Treatment and prognosis\", section on 'General treatment guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with BPD often interpret neutral events, words, or faces as \"negative\" [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Thus, the patient is prone to misinterpret relatively minor disagreements or adverse events as a sign that the caretaker wants to terminate the relationship. The patient often reacts with anger or threats of self harm, which can alienate the support person, who then really does want to end the relationship. This heightened sensitivity to actual or perceived rejection can lead patients to feel more comfortable or secure with a transitional object, such as a pet or stuffed animal, than with other people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Affective instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients experience repeated and marked mood changes throughout the course of a single day, with moment to moment fluctuations often triggered by environmental stressors. Periods of euthymia alternate with intense, episodic dysphoria that includes depression, anxiety, and irritability. Angry outbursts triggered by dissatisfaction with a caregiver are often followed by feelings of shame, guilt, and worthlessness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Impulsivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impetuous and self-damaging behavior is common and can take many forms. Patients abuse substances, binge eat, engage in unsafe sex, spend money irresponsibly, and drive recklessly. In addition, patients can suddenly quit a job that is promising or end a relationship that has the potential to last, thereby sabotaging their own success. Impulsivity can also manifest with immature and regressive behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychologic functioning in patients with BPD is impaired in many domains. A meta-analysis comparing patients with healthy controls found that cognitive functioning in patients was substantially and significantly poorer on tests of [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Attention",
"     </li>",
"     <li>",
"      Cognitive flexibility",
"     </li>",
"     <li>",
"      Learning and memory",
"     </li>",
"     <li>",
"      Planning",
"     </li>",
"     <li>",
"      Processing speed",
"     </li>",
"     <li>",
"      Visuospatial abilities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings demonstrate widespread neuropsychologic deficits linked largely to frontal lobe functioning, and support the idea that many symptoms of the disorder, such as affective instability and identity disturbance, are due to disrupted connections between the prefrontal cortex and other brain regions controlling higher cognitive functions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Comorbid psychopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axis I disorders are common in patients with BPD, especially mood, anxiety, substance use, and eating disorders (",
"    <a class=\"graphic graphic_table graphicRef52837 \" href=\"UTD.htm?13/6/13421\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/7,32-34\">",
"     7,32-34",
"    </a>",
"    ]. An epidemiologic survey found that 85 percent of individuals with BPD have at least one comorbid axis I disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/6\">",
"     6",
"    </a>",
"    ]. The mean number of comorbid Axis I disorders was 3.2 in the epidemiologic survey and 3.4 in a study of borderline outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/6,34\">",
"     6,34",
"    </a>",
"    ]. This comorbidity has accounted for much of the functional impairment in the individuals with BPD in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/6\">",
"     6",
"    </a>",
"    ], but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/35\">",
"     35",
"    </a>",
"    ]. Acute exacerbations of Axis I disorders, sometimes accompanied by suicidal thoughts or attempts, often precipitate treatment seeking or hospitalization (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Suicide'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients with BPD frequently meet criteria for other personality disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/6,36\">",
"     6,36",
"    </a>",
"    ]. It is not clear which personality disorders are most commonly comorbid with BPD, because the results vary across different studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should expect recurrent suicidal threats, gestures, and attempts. The behavior is so common that it constitutes one of the DSM-IV-TR diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef63127 \" href=\"UTD.htm?42/42/43691\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approximately 8 to 12 percent of individuals with BPD commit suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. It is not possible to compare the rate of suicide in patients with BPD to suicide rates in the general population or in other diagnostic groups, since no study has produced a standardized mortality ratio (observed",
"    <span class=\"nowrap\">",
"     deaths/expected",
"    </span>",
"    deaths) for BPD.",
"   </p>",
"   <p>",
"    Assessing the current risk of a patient's suicidal intent is difficult. Years of suicide threats and medically benign suicide gestures may precede a completed suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/39\">",
"     39",
"    </a>",
"    ]. The literature has identified numerous risk factors for suicidality, but none of these is consistent across the various studies. Even when patients are monitored carefully, it is difficult to predict suicidality, because it can arise suddenly and patients act impulsively.",
"   </p>",
"   <p>",
"    Patients may also engage in self-injurious behavior that is not intended as suicide, such as cutting or burning themselves. The patient can usually acknowledge the behavior as a compulsive act that relieves tension and lacks suicidal intent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/40\">",
"     40",
"    </a>",
"    ]. Nevertheless, such behavior should be taken as seriously as a suicide attempt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link&amp;anchor=H2#H2\">",
"     \"Borderline personality disorder: Treatment and prognosis\", section on 'General treatment guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suicidality in patients with BPD should be managed in the following manner [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assess patients carefully for suicide risk and document the findings",
"     </li>",
"     <li>",
"      Take all suicidal ideation and threats seriously",
"     </li>",
"     <li>",
"      Understand that a \"contract for safety\" does not obviate the need for a comprehensive clinical evaluation",
"     </li>",
"     <li>",
"      Address chronic suicidality in therapy",
"     </li>",
"     <li>",
"      Take action for acute suicidality, such as hospitalization",
"     </li>",
"     <li>",
"      Involve family members or significant others when clinically appropriate",
"     </li>",
"     <li>",
"      Consult a colleague if acute suicidality is not responding to treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link\">",
"     \"Borderline personality disorder: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study found that overall, women and men with BPD displayed more similarities than differences in their clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/41\">",
"     41",
"    </a>",
"    ]. Among the variables for which there were no significant differences were history of childhood trauma, current psychosocial functioning, and rate of comorbid major depression. However, significant differences were found between women and men with BPD in the frequency of certain comorbid disorders, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Posttraumatic stress disorder (51 percent of women versus 31 percent of men)",
"     </li>",
"     <li>",
"      Eating disorder (42 versus 18 percent)",
"     </li>",
"     <li>",
"      Substance use disorder (58 versus 85 percent)",
"     </li>",
"     <li>",
"      Antisocial personality disorder (10 versus 30 percent)",
"     </li>",
"     <li>",
"      Narcissistic personality disorder (5 versus 22 percent)",
"     </li>",
"     <li>",
"      Schizotypal personality disorder (10 versus 25 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with BPD, identity disturbance (unstable self-image or sense of self) was present in significantly more women compared to men (67 versus 48 percent). There were no significant differences for the remaining eight diagnostic criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of BPD is based upon symptoms specific to BPD as well as symptoms that are present in all personality disorders. Clinicians should use all available sources to make the diagnosis, including the patient's self-reported clinical history, the clinician's observations during interviews, and information from family, friends, and medical records.",
"   </p>",
"   <p>",
"    We recommend clinicians ask patients about each of the nine criteria that define the diagnosis of BPD in the American Psychiatric Association Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef63127 \" href=\"UTD.htm?42/42/43691\">",
"     table 3",
"    </a>",
"    ). The nine criteria involve enduring problems with interpersonal functioning, affect, impulse control, and cognition. BPD is diagnosed in patients who meet at least five of the nine listed criteria. No single criterion is absolutely required to make the diagnosis, which is recorded on Axis II. Clinicians should also ask about the six general criteria that are each required to diagnose any personality disorder described in DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef78113 \" href=\"UTD.htm?38/41/39579\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The World Health Organization International Classification of Diseases-10th revision (ICD-10) uses the term \"emotionally unstable personality disorder, borderline type\" to classify these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/42\">",
"     42",
"    </a>",
"    ]. The ICD-10 diagnostic criteria are similar to those of DSM-IV-TR (",
"    <a class=\"graphic graphic_table graphicRef57216 \" href=\"UTD.htm?5/56/6027\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All nine of the DSM-IV-TR diagnostic criteria are common in patients with BPD. The frequency of each diagnostic criterion in a group of 201 patients with BPD was [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Affective instability (95 percent)",
"     </li>",
"     <li>",
"      Inappropriate anger (87 percent)",
"     </li>",
"     <li>",
"      Impulsivity (81 percent)",
"     </li>",
"     <li>",
"      Unstable relationships (79 percent)",
"     </li>",
"     <li>",
"      Feelings of emptiness (71 percent)",
"     </li>",
"     <li>",
"      Paranoia or dissociation (68 percent)",
"     </li>",
"     <li>",
"      Identity disturbance (61 percent)",
"     </li>",
"     <li>",
"      Abandonment fears (60 percent)",
"     </li>",
"     <li>",
"      Suicidality or self-injury (60 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective follow-up two years later showed that the rank ordering of prevalence was exactly the same as at baseline.",
"   </p>",
"   <p>",
"    Onset of BPD begins in adolescence or early adulthood, with maladaptive traits that endure over time and are of long duration. DSM-IV-TR implies that in adults with the disorder, the stable pattern of psychopathology is present for years, but does not specify the number of years. Semi-structured interviews that are used to diagnose personality disorders generally require a minimum duration of two to five years. (\"See Diagnostic measures\" below).",
"   </p>",
"   <p>",
"    The diagnosis is typically not given to children or young adolescents. Traits of the disorder that appear in childhood may be specific to a particular developmental stage and change as the individual reaches adulthood.",
"   </p>",
"   <p>",
"    Symptoms of BPD often fluctuate in the short term and are not continuously present. A study of diagnostic stability found that among patients diagnosed with BPD at baseline, only 41 percent remained at diagnostic threshold (met at least five out of nine criteria) for each of the following 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/44\">",
"     44",
"    </a>",
"    ]. The phrase \"borderline personality features\" is recorded on Axis II if prominent maladaptive features are present in numbers that are insufficient to meet the diagnostic threshold for BPD.",
"   </p>",
"   <p>",
"    Making the diagnosis of BPD can be difficult if comorbid axis I disorders are present, which happens frequently. Symptoms of the Axis I condition, such as an episodic mood disorder, can overlap with and overshadow the stable psychopathology of BPD. This may lead to under diagnosis of BPD. A study found that personality disorders diagnosed during a major depressive episode were as valid as those diagnosed in the absence of depression, indicating that it is possible to tease out significant personality psychopathology when a patient is depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Comorbid psychopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Over-diagnosis of BPD occurs when the term is applied indiscriminately or pejoratively to angry, irritating, demanding, difficult, or self-destructive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/46\">",
"     46",
"    </a>",
"    ]. The diagnosis should be used in accordance with the DSM-IV-TR definition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Screening and diagnostic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A self-report measure called the McLean Screening Instrument for Borderline Personality Disorder is available to screen patients for the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/47\">",
"     47",
"    </a>",
"    ]. Each of the 10 items is dichotomous, and the instrument has good psychometric properties (sensitivity 0.81 and specificity 0.85). This tool is intended only for screening and not for rendering a final diagnosis.",
"   </p>",
"   <p>",
"    Several validated personality disorder assessment instruments are available to diagnose any of the personality disorders, including BPD. These instruments systematically assess each criterion for every personality disorder. Self-report instruments such as the Personality Diagnostic Questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/48\">",
"     48",
"    </a>",
"    ] have the advantage of saving interviewer time, but often yield false positive diagnoses. Interviewer-administered instruments such as the Structured Clinical Interview for DSM-IV Axis II Personality Disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/49\">",
"     49",
"    </a>",
"    ] enable the interviewer to clarify contradictory or ambiguous patient responses, but are labor intensive and generally reserved for specialized evaluation, treatment, or research settings.",
"   </p>",
"   <p>",
"    There are also validated instruments specifically designed for diagnosing only BPD. One example is the self-report Borderline Symptom List [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inter-rater and test-retest reliabilities among different semi-structured interviews used to diagnose BPD are good to excellent (kappa = 0.68 to 0.96 for inter-rater and kappa = 0.40 to 0.85 for test-retest) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/51\">",
"     51",
"    </a>",
"    ]. Reliability is mostly a function of interviewer training and experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many Axis I and Axis II disorders resemble BPD. The diagnostic evaluation needs to distinguish these other disorders from BPD in order to properly direct treatment.",
"   </p>",
"   <p>",
"    The Axis I and Axis II disorders that resemble BPD can also occur in conjunction with BPD. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Comorbid psychopathology'",
"    </a>",
"    above.) Every DSM-IV-TR disorder that is present should be diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Axis I disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain symptoms of specific axis I disorders are identical or similar to symptoms of BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ]. The greatest amount of overlap occurs with mood disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder &mdash; The alternating mood syndromes (\"mood swings\") of bipolar I, bipolar II, or cyclothymic disorder can resemble the affective instability of BPD. The distinguishing feature is that the depressive or mood elevated syndromes in bipolar disorder are longer in duration compared to the labile affective states of BPD. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Affective instability'",
"      </a>",
"      above.) In addition, mood syndromes in bipolar disorder are less connected to events in the environment, compared to the affective instability of BPD that is often triggered by stressors such as perceived rejection or failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Major depression &mdash; The dysphoria that characterizes major depression is present most of the day, nearly every day, for at least two weeks, whereas BPD is marked by affective states that fluctuate within a single day. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Affective instability'",
"      </a>",
"      above.) Major depression also involves sustained neurovegetative symptoms related to sleep, appetite, and energy, which are not features of BPD. In addition, BPD is marked by symptoms such as identity disturbance and frantic efforts to avoid abandonment, which are not part of major depression or other axis I disorders. The symptoms of loneliness and emptiness is also indicative of BPD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dysthymia &mdash; Chronic dysphoria, overeating, and low self-esteem are symptoms of dysthymia, and can also occur in BPD. Dysthymia involves sustained symptoms related to sleep and energy, which are not part of BPD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Posttraumatic stress disorder &mdash; A history of trauma, which is central to the diagnosis of posttraumatic stress disorder, often occurs in BPD as well. In posttraumatic stress disorder, onset of symptoms in response to a specific traumatic event is often rapid (and usually occurs in adulthood, whereas in BPD, onset of symptoms occurs in adolescence or early adulthood). Posttraumatic stress disorder is characterized by symptoms of reexperiencing the traumatic event, avoidance and numbing, and increased arousal, which are not part of BPD. Problems with self-image and interpersonal relationships characteristic of BPD are not typically part of posttraumatic stress disorder in the absence of personality pathology. In addition, exacerbation of symptoms in posttraumatic stress disorder is due to specific environmental triggers, whereas symptoms of BPD are exacerbated by more general stressors and frustrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link&amp;anchor=H15#H15\">",
"       \"Postpartum psychosis: Epidemiology, clinical manifestations, and assessment\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dissociative identity disorder &mdash; Disturbance of identity is common to both BPD and dissociative identity disorder. The distinguishing feature is that dissociative identity disorder is characterized by two or more distinct identities or personality states, each with its own enduring pattern of behavior, whereas the identity disturbance in BPD consists of an unstable and fluctuating sense of self, with sudden changes in self-image, goals, and values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Axis II disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPD shares certain features with other personality disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/19/10553/abstract/1\">",
"     1",
"    </a>",
"    ]. The greatest amount of overlap occurs with the other cluster B (dramatic, emotional, erratic) personality disorders (",
"    <a class=\"graphic graphic_table graphicRef69002 \" href=\"UTD.htm?21/31/22012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antisocial personality disorder &mdash; The manipulative behavior characteristic of antisocial personality disorder is directed at gaining power or material gratification, whereas patients with BPD are manipulative for the purpose of gaining the concern of caretakers. Patients with antisocial personality disorder are also more emotionally stable and aggressive compared to patients with BPD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link&amp;anchor=H17#H17\">",
"       \"Personality disorders\", section on 'Antisocial personality disorder'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histrionic personality disorder &mdash; Affective instability as well as manipulative and attention-seeking behavior can occur in both histrionic personality disorder and BPD. The two disorders can be distinguished by symptoms that occur only in BPD, such as self-destructive behavior, frequent angry disruptions in relationships, and chronic feelings of emptiness.",
"     </li>",
"     <li>",
"      Narcissistic personality disorder &mdash; Angry reactions to relatively minor provocations characterize both narcissistic personality disorder and BPD. In narcissistic personality disorder, this behavior occurs in the context of a stable, grandiose self-image and without the self-destructive behavior, impulsivity, and fear of abandonment that mark BPD.",
"     </li>",
"     <li>",
"      Paranoid personality disorder &mdash; Suspiciousness or paranoia, as well as angry reactions to minor stimuli, can occur in both paranoid personality disorder and BPD. Paranoid personality disorder is distinguished by a more pervasive suspiciousness and stable self-image, and lacks the self-destructive behavior, impulsivity, and fear of abandonment that characterize BPD.",
"     </li>",
"     <li>",
"      Schizotypal personality disorder &mdash; Both schizotypal personality disorder and BPD share psychotic-like symptoms and difficulty with relationships. Patients with schizotypal personality disorder are more emotionally stable and less impulsive, and their difficulty with relationships stems from odd thinking and strange behavior. In BPD, the psychotic-like episodes are more transient, and the difficulty with relationships is due to affective instability and angry outbursts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link&amp;anchor=H13#H13\">",
"       \"Personality disorders\", section on 'Schizotypal personality disorder'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dependent personality disorder &mdash; The excessive need to be taken care of and fear of abandonment seen in dependent personality disorder leads to increasing appeasement and submissiveness when relationships are threatened, whereas the patient with BPD reacts with rage and feelings of emptiness. In addition, relationships in dependent personality disorder are more stable than those of BPD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/10/16546?source=see_link\">",
"       \"Patient information: Borderline personality disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BPD is a common illness, with a point prevalence in the US general population greater than of 1 percent and a lifetime prevalence of approximately 6 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ratio of women to men with BPD in clinical studies is about three to one, but in epidemiologic studies the prevalence rates for women and men are essentially equal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of the disorder is unknown. Most hypotheses state that a combination of interacting factors causes BPD, including environmental experiences such as childhood trauma, genetic predisposition, and other biological abnormalities. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The core features of the disorder consist of a pervasive and enduring pattern of instability of interpersonal relationships, self-image, and affect, and marked impulsivity. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comorbid psychiatric disorders occur frequently in patients with BPD. &nbsp;The most common are mood, anxiety, and substance use disorders. Comorbid personality disorders are also common. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suicidality in the form of threats, gestures, and attempts is common and should be closely monitored. Predicting suicide is very difficult, and approximately 8 to 12 percent of patients commit suicide. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should ask patients about each of the nine possible criteria for BPD listed in DSM-IV-TR (",
"      <a class=\"graphic graphic_table graphicRef63127 \" href=\"UTD.htm?42/42/43691\">",
"       table 3",
"      </a>",
"      ). At least five of these criteria are required to diagnose BPD. In addition, clinicians should ask about each of the six general criteria that are each required to diagnose any personality disorder (",
"      <a class=\"graphic graphic_table graphicRef78113 \" href=\"UTD.htm?38/41/39579\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes mood disorders, posttraumatic stress disorder, dissociative identity disorder, and other personality disorders. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/2\">",
"      Stern, A. Psychoanalytic investigation of and therapy in the borderline group of neuroses. Psychoanal Q 1938; 7:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/3\">",
"      Blashfield RK, Intoccia V. Growth of the literature on the topic of personality disorders. Am J Psychiatry 2000; 157:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/4\">",
"      Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001; 158:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/5\">",
"      Grant BF, Chou SP, Goldstein RB, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/6\">",
"      Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 62:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/7\">",
"      Gross R, Olfson M, Gameroff M, et al. Borderline personality disorder in primary care. Arch Intern Med 2002; 162:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/8\">",
"      Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry 2005; 162:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/9\">",
"      Chavira DA, Grilo CM, Shea MT, et al. Ethnicity and four personality disorders. Compr Psychiatry 2003; 44:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/10\">",
"      Soeteman DI, Hakkaart-van Roijen L, Verheul R, Busschbach JJ. The economic burden of personality disorders in mental health care. J Clin Psychiatry 2008; 69:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/11\">",
"      Bender DS, Skodol AE, Pagano ME, et al. Prospective assessment of treatment use by patients with personality disorders. Psychiatr Serv 2006; 57:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/12\">",
"      Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science 2002; 297:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/13\">",
"      Zanarini MC. Childhood experiences associated with the development of borderline personality disorder. Psychiatr Clin North Am 2000; 23:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/14\">",
"      Zanarini MC, Williams AA, Lewis RE, et al. Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry 1997; 154:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/15\">",
"      Johnson JG, Cohen P, Brown J, et al. Childhood maltreatment increases risk for personality disorders during early adulthood. Arch Gen Psychiatry 1999; 56:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/16\">",
"      Fossati A, Madeddu F, Maffei C. Borderline Personality Disorder and childhood sexual abuse: a meta-analytic study. J Pers Disord 1999; 13:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/17\">",
"      Klonsky ED, Moyer A. Childhood sexual abuse and non-suicidal self-injury: meta-analysis. Br J Psychiatry 2008; 192:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/18\">",
"      Rind B, Tromovitch P, Bauserman R. A meta-analytic examination of assumed properties of child sexual abuse using college samples. Psychol Bull 1998; 124:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/19\">",
"      Torgersen S, Lygren S, Oien PA, et al. A twin study of personality disorders. Compr Psychiatry 2000; 41:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/20\">",
"      Kendler KS, Aggen SH, Czajkowski N, et al. The structure of genetic and environmental risk factors for DSM-IV personality disorders: a multivariate twin study. Arch Gen Psychiatry 2008; 65:1438.",
"     </a>",
"    </li>",
"    <li>",
"     Distel, MA, Trull, TJ, Derom, CA, et al. Heritability of borderline personality disorder features is similar across three countries. Psychol Med 2008: 38:1219.",
"    </li>",
"    <li>",
"     Linehan, MM. Cognitive behavioral treatment of borderline personality disorder. Guilford Press, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/23\">",
"      Stanley B, Siever LJ. The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry 2010; 167:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/24\">",
"      Hansenne M, Pitchot W, Pinto E, et al. 5-HT1A dysfunction in borderline personality disorder. Psychol Med 2002; 32:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/25\">",
"      Soloff P, Nutche J, Goradia D, Diwadkar V. Structural brain abnormalities in borderline personality disorder: a voxel-based morphometry study. Psychiatry Res 2008; 164:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/26\">",
"      Sanislow CA, Grilo CM, McGlashan TH. Factor analysis of the DSM-III-R borderline personality disorder criteria in psychiatric inpatients. Am J Psychiatry 2000; 157:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/27\">",
"      Lieb K, Zanarini MC, Schmahl C, et al. Borderline personality disorder. Lancet 2004; 364:453.",
"     </a>",
"    </li>",
"    <li>",
"     Gunderson, JG, Links, PS. Borderline Personality Disorder, A Clinical Guide. American Psychiatric Press, Washington DC 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/29\">",
"      Korfine L, Hooley JM. Directed forgetting of emotional stimuli in borderline personality disorder. J Abnorm Psychol 2000; 109:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/30\">",
"      Donegan NH, Sanislow CA, Blumberg HP, et al. Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry 2003; 54:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/31\">",
"      Ruocco AC. The neuropsychology of borderline personality disorder: a meta-analysis and review. Psychiatry Res 2005; 137:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/32\">",
"      Shea MT, Stout RL, Yen S, et al. Associations in the course of personality disorders and Axis I disorders over time. J Abnorm Psychol 2004; 113:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/33\">",
"      Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998; 155:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/34\">",
"      Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry 1999; 40:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/35\">",
"      Skodol AE, Gunderson JG, McGlashan TH, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry 2002; 159:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/36\">",
"      American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001; 158:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/37\">",
"      Pompili M, Girardi P, Ruberto A, Tatarelli R. Suicide in borderline personality disorder: a meta-analysis. Nord J Psychiatry 2005; 59:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/38\">",
"      Paris J. Implications of long-term outcome research for the management of patients with borderline personality disorder. Harv Rev Psychiatry 2002; 10:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/39\">",
"      Soloff PH, Fabio A. Prospective predictors of suicide attempts in borderline personality disorder at one, two, and two-to-five year follow-up. J Pers Disord 2008; 22:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/40\">",
"      Leibenluft, E, Gardner, DL, Cowdry, RW. The inner experience of the borderline self-mutilator. J Personal Disorders 1987; 1:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/41\">",
"      Johnson DM, Shea MT, Yen S, et al. Gender differences in borderline personality disorder: findings from the Collaborative Longitudinal Personality Disorders Study. Compr Psychiatry 2003; 44:284.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/43\">",
"      McGlashan TH, Grilo CM, Sanislow CA, et al. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders. Am J Psychiatry 2005; 162:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/44\">",
"      Shea MT, Stout R, Gunderson J, et al. Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry 2002; 159:2036.",
"     </a>",
"    </li>",
"    <li>",
"     Morey, LC, Shea, MT, Markowitz, JC, et al. State effects of major depression on the assessment of personality and personality disorder. Am J Psychiatry, 2010 Feb 16 Epub ahead of print.",
"    </li>",
"    <li>",
"     First, MB, Frances, A, Pincus, HA. DSM-IV Guidebook. Washington, D.C.: American Psychiatric Press, Inc., 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/47\">",
"      Zanarini MC, Vujanovic AA, Parachini EA, et al. A screening measure for BPD: the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD). J Pers Disord 2003; 17:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/48\">",
"      Hyler SE, Skodol AE, Kellman HD, et al. Validity of the Personality Diagnostic Questionnaire--revised: comparison with two structured interviews. Am J Psychiatry 1990; 147:1043.",
"     </a>",
"    </li>",
"    <li>",
"     First, MB, Gibbon, M, Spitzer, RL, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, D.C.: American Psychiatric Press, Inc., 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/19/10553/abstract/50\">",
"      Bohus M, Kleindienst N, Limberger MF, et al. The short version of the Borderline Symptom List (BSL-23): development and initial data on psychometric properties. Psychopathology 2009; 42:32.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Borderline Personality Disorder: Treatment and Mangaement. 2009. file://www.nice.org.uk/CG78. Accessed 2/12/10.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6619 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10553=[""].join("\n");
var outline_f10_19_10553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Economic costs and health care utilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychosocial causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic basis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biological correlates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interpersonal difficulties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Affective instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Impulsivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Comorbid psychopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Suicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gender differences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Screening and diagnostic measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Axis I disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Axis II disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/6619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/6619|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/31/22012\" title=\"table 1\">",
"      Personality dis DSM-IV-TR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/6/13421\" title=\"table 2\">",
"      BPD Axis I disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/42/43691\" title=\"table 3\">",
"      DSM-IV-TR BPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/41/39579\" title=\"table 4\">",
"      Criteria personality disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/56/6027\" title=\"table 5\">",
"      ICD-10 dx borderline type",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=related_link\">",
"      Borderline personality disorder: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/10/16546?source=related_link\">",
"      Patient information: Borderline personality disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=related_link\">",
"      Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_19_10554="Symptothermal chart";
var content_f10_19_10554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Symptothermal chart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Institute for Reproductive Health, Georgetown University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10554=[""].join("\n");
var outline_f10_19_10554=null;
var title_f10_19_10555="Neutropenia and infectious risk";
var content_f10_19_10555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relation of absolute neutrophil count to risk of infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Absolute neutrophil count",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;1500/microL (&gt;1.5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        /liter)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1000 to 1500/microL",
"       </td>",
"       <td>",
"        No significant risk of infection; fever can be managed on an outpatient basis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        500 to 1000/microL",
"       </td>",
"       <td>",
"        Some risk of infection; fever can occasionally be managed on an outpatient basis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;500/microL",
"       </td>",
"       <td>",
"        Significant risk of infection; fever should always be managed on an inpatient basis with parenteral antibiotics; few clinical signs of infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200/microL",
"       </td>",
"       <td>",
"        Very significant risk of infection; fever should always be managed on an inpatient basis with parenteral antibiotics; few or no clinical signs of infection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10555=[""].join("\n");
var outline_f10_19_10555=null;
var title_f10_19_10556="Causes of aortic regurgitation";
var content_f10_19_10556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Leaflet abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocarditis (bacterial or marantic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bicuspid aortic valve",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myxomatous degeneration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ankylosing spondylitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acromegaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fenfluramine-phentermine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Aortic root or ascending aorta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortitis (eg, syphilis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reactive arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ankylosing spondylitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dissecting aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Marfan syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ehlers-Danlos syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pseudoxanthoma elasticum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteogenesis imperfecta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Annuloaortic ectasia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10556=[""].join("\n");
var outline_f10_19_10556=null;
var title_f10_19_10557="Pacemaker algorithm rate adaptive";
var content_f10_19_10557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Simplified pacemaker algorithm for use with rate adaptive pacemakers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 138px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simplified algorithm for the choice of pacemaker mode assuming that a rate-responsive pacemaker (DDDR or VVIR) will be used.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of MD McGoon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10557=[""].join("\n");
var outline_f10_19_10557=null;
var title_f10_19_10558="Modified FOLFOX7 regimen";
var content_f10_19_10558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified FOLFOX7 chemotherapy for gastrointestinal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV*",
"       </td>",
"       <td>",
"        Dilute with 250 mL 5 percent dextrose in water (D5W)",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL D5W",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over two hours concurrent with oxaliplatin.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 500 to 1000 mL D5W and administer over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin and FU are classified as irritants but oxaliplatin can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factor not justified (estimated risk of febrile neutropenia &lt;5 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of oxaliplatin may be needed for severe renal impairment",
"        <sup>",
"         [2]",
"        </sup>",
"        . A lower starting dose of FU may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment cycle one week for total white blood cell count &lt;3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , absolute neutrophil count &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or platelets &lt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce dose of infusional FU by 20 percent and reduce the dose of oxaliplatin from 85 to 65 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting longer than seven days, decrease oxaliplatin dose by 25 percent. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment for grade 2 or worse diarrhea and restart at a lower dose after complete resolution",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [4]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Grothey A, et al. Intermittent oxaliplatin administration and time to treatment failure in metastatic colorectal cancer: Final results of the phase III CONcePT trial (abstract). J Clin Oncol 2008; 26s:abstr 4010.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10558=[""].join("\n");
var outline_f10_19_10558=null;
var title_f10_19_10559="Patient position for suprapubic aspiration";
var content_f10_19_10559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positioning of the patient for suprapubic bladder aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The child is restrained in the supine and frog leg position. This permits adequate stabilization of the pelvis. The site for needle insertion is in the midline, approximately one to two centimeters above the pubic symphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: King C, Henreting FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_19_10559=[""].join("\n");
var outline_f10_19_10559=null;
